index	sentence	Gene	Disease	prediction
0	Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours - implications for personalised cancer medicine	K-Ras	colorectal tumours	1.0
1	Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours - implications for personalised cancer medicine	K-Ras	cancer	1.0
2	Response to EGFR-targeted therapies in colorectal cancer patients has been convincingly associated with Kirsten-Ras (K-Ras) mutation status	EGFR	colorectal cancer	0.0
3	Response to EGFR-targeted therapies in colorectal cancer patients has been convincingly associated with Kirsten-Ras (K-Ras) mutation status	Kirsten-Ras	colorectal cancer	1.0
4	Response to EGFR-targeted therapies in colorectal cancer patients has been convincingly associated with Kirsten-Ras (K-Ras) mutation status	K-Ras	colorectal cancer	0.0
5	Colorectal tumours (n=106) were screened for additional K-Ras mutations, phenotypes compared in transformation and Ras GTPase activating assays and gene and pathway changes induced by individual K-Ras mutants identified by microarray analysis	K-Ras	Colorectal tumours	1.0
6	Colorectal tumours (n=106) were screened for additional K-Ras mutations, phenotypes compared in transformation and Ras GTPase activating assays and gene and pathway changes induced by individual K-Ras mutants identified by microarray analysis	K-Ras	Colorectal tumours	1.0
7	Four additional K-Ras mutations (Leu19Phe (1 out of 106 tumours), Lys117Asn (1 out of 106), Ala146Thr (7 out of 106) and Arg164Gln (1 out of 106)) were identified	K-Ras	tumours	1.0
8	We additionally identified a new K-Ras gene amplification event, present in approximately 2% of tumours.	K-Ras	tumours	1.0
9	The identification of mutations outwith previously described hotspot codons increases the K-Ras mutation burden in colorectal tumours by one-third	K-Ras	colorectal tumours	1.0
10	A genetic model for colorectal cancer highlighted key genes, including the tumour suppressor genes adenomatous polyposis coli (APC) and p53 and the oncogene Kirsten-Ras (K-Ras), the progressive acquisition of mutations in which was proposed to regulate the adenoma-carcinoma transition (Vogelstein et al, 1988)	p53	colorectal cancer	1.0
11	A genetic model for colorectal cancer highlighted key genes, including the tumour suppressor genes adenomatous polyposis coli (APC) and p53 and the oncogene Kirsten-Ras (K-Ras), the progressive acquisition of mutations in which was proposed to regulate the adenoma-carcinoma transition (Vogelstein et al, 1988)	Kirsten-Ras	colorectal cancer	1.0
12	A genetic model for colorectal cancer highlighted key genes, including the tumour suppressor genes adenomatous polyposis coli (APC) and p53 and the oncogene Kirsten-Ras (K-Ras), the progressive acquisition of mutations in which was proposed to regulate the adenoma-carcinoma transition (Vogelstein et al, 1988)	K-Ras	colorectal cancer	1.0
13	A genetic model for colorectal cancer highlighted key genes, including the tumour suppressor genes adenomatous polyposis coli (APC) and p53 and the oncogene Kirsten-Ras (K-Ras), the progressive acquisition of mutations in which was proposed to regulate the adenoma-carcinoma transition (Vogelstein et al, 1988)	p53	tumour	1.0
14	A genetic model for colorectal cancer highlighted key genes, including the tumour suppressor genes adenomatous polyposis coli (APC) and p53 and the oncogene Kirsten-Ras (K-Ras), the progressive acquisition of mutations in which was proposed to regulate the adenoma-carcinoma transition (Vogelstein et al, 1988)	Kirsten-Ras	tumour	1.0
15	A genetic model for colorectal cancer highlighted key genes, including the tumour suppressor genes adenomatous polyposis coli (APC) and p53 and the oncogene Kirsten-Ras (K-Ras), the progressive acquisition of mutations in which was proposed to regulate the adenoma-carcinoma transition (Vogelstein et al, 1988)	K-Ras	tumour	1.0
16	A genetic model for colorectal cancer highlighted key genes, including the tumour suppressor genes adenomatous polyposis coli (APC) and p53 and the oncogene Kirsten-Ras (K-Ras), the progressive acquisition of mutations in which was proposed to regulate the adenoma-carcinoma transition (Vogelstein et al, 1988)	p53	adenomatous polyposis coli	1.0
17	A genetic model for colorectal cancer highlighted key genes, including the tumour suppressor genes adenomatous polyposis coli (APC) and p53 and the oncogene Kirsten-Ras (K-Ras), the progressive acquisition of mutations in which was proposed to regulate the adenoma-carcinoma transition (Vogelstein et al, 1988)	Kirsten-Ras	adenomatous polyposis coli	1.0
18	A genetic model for colorectal cancer highlighted key genes, including the tumour suppressor genes adenomatous polyposis coli (APC) and p53 and the oncogene Kirsten-Ras (K-Ras), the progressive acquisition of mutations in which was proposed to regulate the adenoma-carcinoma transition (Vogelstein et al, 1988)	K-Ras	adenomatous polyposis coli	1.0
19	A genetic model for colorectal cancer highlighted key genes, including the tumour suppressor genes adenomatous polyposis coli (APC) and p53 and the oncogene Kirsten-Ras (K-Ras), the progressive acquisition of mutations in which was proposed to regulate the adenoma-carcinoma transition (Vogelstein et al, 1988)	p53	APC	1.0
20	A genetic model for colorectal cancer highlighted key genes, including the tumour suppressor genes adenomatous polyposis coli (APC) and p53 and the oncogene Kirsten-Ras (K-Ras), the progressive acquisition of mutations in which was proposed to regulate the adenoma-carcinoma transition (Vogelstein et al, 1988)	Kirsten-Ras	APC	1.0
21	A genetic model for colorectal cancer highlighted key genes, including the tumour suppressor genes adenomatous polyposis coli (APC) and p53 and the oncogene Kirsten-Ras (K-Ras), the progressive acquisition of mutations in which was proposed to regulate the adenoma-carcinoma transition (Vogelstein et al, 1988)	K-Ras	APC	1.0
22	A genetic model for colorectal cancer highlighted key genes, including the tumour suppressor genes adenomatous polyposis coli (APC) and p53 and the oncogene Kirsten-Ras (K-Ras), the progressive acquisition of mutations in which was proposed to regulate the adenoma-carcinoma transition (Vogelstein et al, 1988)	p53	adenoma-carcinoma	1.0
23	A genetic model for colorectal cancer highlighted key genes, including the tumour suppressor genes adenomatous polyposis coli (APC) and p53 and the oncogene Kirsten-Ras (K-Ras), the progressive acquisition of mutations in which was proposed to regulate the adenoma-carcinoma transition (Vogelstein et al, 1988)	Kirsten-Ras	adenoma-carcinoma	1.0
24	A genetic model for colorectal cancer highlighted key genes, including the tumour suppressor genes adenomatous polyposis coli (APC) and p53 and the oncogene Kirsten-Ras (K-Ras), the progressive acquisition of mutations in which was proposed to regulate the adenoma-carcinoma transition (Vogelstein et al, 1988)	K-Ras	adenoma-carcinoma	1.0
25	We subsequently refined this model (Smith et al, 2002), highlighting a significant increase in K-Ras mutation frequency in Dukes' C tumours, suggesting that K-Ras mutation status may be an important determinant of tumour progression	K-Ras	Dukes' C tumours	1.0
26	We subsequently refined this model (Smith et al, 2002), highlighting a significant increase in K-Ras mutation frequency in Dukes' C tumours, suggesting that K-Ras mutation status may be an important determinant of tumour progression	K-Ras	tumour	1.0
27	We subsequently refined this model (Smith et al, 2002), highlighting a significant increase in K-Ras mutation frequency in Dukes' C tumours, suggesting that K-Ras mutation status may be an important determinant of tumour progression	K-Ras	Dukes' C tumours	1.0
28	We subsequently refined this model (Smith et al, 2002), highlighting a significant increase in K-Ras mutation frequency in Dukes' C tumours, suggesting that K-Ras mutation status may be an important determinant of tumour progression	K-Ras	tumour	1.0
29	We additionally used comparative genomic hybridisation (CGH) analysis to identify common chromosomal aberrations in colorectal tumours, and highlighted an amplification of the region of chromosome 12p where the K-Ras gene is localised (Leslie et al, 2003)	K-Ras	colorectal tumours	1.0
30	We and others have shown that K-Ras mutations are associated with significantly reduced survival in colorectal cancer patients (Andreyev et al, 2001; Conlin et al, 2005), although previous data is not entirely consistent (Etienne-Grimaldi et al, 2008; Winder et al, 2009)	K-Ras	colorectal cancer	0.0
31	K-Ras mutation status has recently been convincingly associated with response to the new generation EGFR antagonists cetuximab (Erbitux) and panitumumab (Vectibix), where response is preferentially observed in wt K-Ras tumours (Lievre et al, 2006; Benvenuti et al, 2007; Khambata-Ford et al, 2007; Freeman et al, 2008; Karapetis et al, 2008; Ramos et al, 2008; Loupakis et al, 2009; Van Cutsem et al, 2009)	K-Ras	K-Ras tumours	1.0
32	K-Ras mutation status has recently been convincingly associated with response to the new generation EGFR antagonists cetuximab (Erbitux) and panitumumab (Vectibix), where response is preferentially observed in wt K-Ras tumours (Lievre et al, 2006; Benvenuti et al, 2007; Khambata-Ford et al, 2007; Freeman et al, 2008; Karapetis et al, 2008; Ramos et al, 2008; Loupakis et al, 2009; Van Cutsem et al, 2009)	EGFR	K-Ras tumours	1.0
33	K-Ras mutation testing is therefore increasingly recommended to facilitate selection of the most appropriate patients for treatment with EGFR antagonists (McNeill, 2008; van Krieken and Tol, 2009).	K-Ras	van Krieken	1.0
34	K-Ras mutation testing is therefore increasingly recommended to facilitate selection of the most appropriate patients for treatment with EGFR antagonists (McNeill, 2008; van Krieken and Tol, 2009).	EGFR	van Krieken	1.0
35	Previous analyses of K-Ras mutations in human tumours have consistently focussed on single-point mutations in codons 12, 13 and 61, where mutation has been shown to result in reduced Ras GAP GTPase activity, locking the protein in the active Ras-GTP conformation (Ellis and Clark, 2000), although additional mutations at codons 19, 22 and 146 have been described in single colorectal tumour case reports (Orita et al, 1991; Miyakura et al, 2002; Akagi et al, 2007).	K-Ras	tumours	1.0
36	Previous analyses of K-Ras mutations in human tumours have consistently focussed on single-point mutations in codons 12, 13 and 61, where mutation has been shown to result in reduced Ras GAP GTPase activity, locking the protein in the active Ras-GTP conformation (Ellis and Clark, 2000), although additional mutations at codons 19, 22 and 146 have been described in single colorectal tumour case reports (Orita et al, 1991; Miyakura et al, 2002; Akagi et al, 2007).	K-Ras	colorectal tumour	1.0
37	B-Raf mutations have also been identified in human cancers, including melanoma and thyroid, ovarian and colorectal tumours, although mutation frequency estimates in colorectal tumours vary from 1 to 20%, and have been particularly associated with tumours deficient in mismatch-repair activity (Wellbrock et al, 2004)	B-Raf	cancers	0.0
38	B-Raf mutations have also been identified in human cancers, including melanoma and thyroid, ovarian and colorectal tumours, although mutation frequency estimates in colorectal tumours vary from 1 to 20%, and have been particularly associated with tumours deficient in mismatch-repair activity (Wellbrock et al, 2004)	B-Raf	melanoma	0.0
39	B-Raf mutations have also been identified in human cancers, including melanoma and thyroid, ovarian and colorectal tumours, although mutation frequency estimates in colorectal tumours vary from 1 to 20%, and have been particularly associated with tumours deficient in mismatch-repair activity (Wellbrock et al, 2004)	B-Raf	ovarian and colorectal tumours	0.0
40	B-Raf mutations have also been identified in human cancers, including melanoma and thyroid, ovarian and colorectal tumours, although mutation frequency estimates in colorectal tumours vary from 1 to 20%, and have been particularly associated with tumours deficient in mismatch-repair activity (Wellbrock et al, 2004)	B-Raf	colorectal tumours	0.0
41	B-Raf mutations have also been identified in human cancers, including melanoma and thyroid, ovarian and colorectal tumours, although mutation frequency estimates in colorectal tumours vary from 1 to 20%, and have been particularly associated with tumours deficient in mismatch-repair activity (Wellbrock et al, 2004)	B-Raf	tumours deficient	0.0
42	The most common B-Raf mutation is a T to A transversion, resulting in a valine to glutamic acid substitution (V600E), present in approximately 90% of B-Raf mutant tumours (Davies et al, 2002), which results in a 500-fold increase in in vitro kinase activity and the induction of cell proliferation and transformation (Wan et al, 2004)	B-Raf	tumours	1.0
43	The most common B-Raf mutation is a T to A transversion, resulting in a valine to glutamic acid substitution (V600E), present in approximately 90% of B-Raf mutant tumours (Davies et al, 2002), which results in a 500-fold increase in in vitro kinase activity and the induction of cell proliferation and transformation (Wan et al, 2004)	B-Raf	tumours	0.0
44	Although K-Ras and B-Raf mutations are found in the same tumour types, they are thought to be mutually exclusive (Wellbrock et al, 2004), providing distinct but related mechanisms for the activation of K-Ras signalling pathways	K-Ras	tumour	1.0
45	Although K-Ras and B-Raf mutations are found in the same tumour types, they are thought to be mutually exclusive (Wellbrock et al, 2004), providing distinct but related mechanisms for the activation of K-Ras signalling pathways	B-Raf	tumour	1.0
46	Although K-Ras and B-Raf mutations are found in the same tumour types, they are thought to be mutually exclusive (Wellbrock et al, 2004), providing distinct but related mechanisms for the activation of K-Ras signalling pathways	K-Ras	tumour	1.0
47	B-Raf mutation status has also recently been associated with response to cetuximab and panitumumab where, like K-Ras, clinical response is limited to wt B-Raf tumours (Di Nicolantonio et al, 2008).	B-Raf	B-Raf tumours	1.0
48	B-Raf mutation status has also recently been associated with response to cetuximab and panitumumab where, like K-Ras, clinical response is limited to wt B-Raf tumours (Di Nicolantonio et al, 2008).	K-Ras	B-Raf tumours	1.0
49	As K-Ras mutations in colorectal tumours are clearly important biomarkers of tumour progression and patient survival and also influence response to new generation EGFR antagonists, we have used a variety of experimental approaches to further investigate inter-individual differences in K-Ras mutation burden.	K-Ras	colorectal tumours	0.0
50	As K-Ras mutations in colorectal tumours are clearly important biomarkers of tumour progression and patient survival and also influence response to new generation EGFR antagonists, we have used a variety of experimental approaches to further investigate inter-individual differences in K-Ras mutation burden.	K-Ras	tumour	0.0
51	As K-Ras mutations in colorectal tumours are clearly important biomarkers of tumour progression and patient survival and also influence response to new generation EGFR antagonists, we have used a variety of experimental approaches to further investigate inter-individual differences in K-Ras mutation burden.	EGFR	colorectal tumours	0.0
52	As K-Ras mutations in colorectal tumours are clearly important biomarkers of tumour progression and patient survival and also influence response to new generation EGFR antagonists, we have used a variety of experimental approaches to further investigate inter-individual differences in K-Ras mutation burden.	K-Ras	colorectal tumours	0.0
53	As K-Ras mutations in colorectal tumours are clearly important biomarkers of tumour progression and patient survival and also influence response to new generation EGFR antagonists, we have used a variety of experimental approaches to further investigate inter-individual differences in K-Ras mutation burden.	EGFR	tumour	0.0
54	As K-Ras mutations in colorectal tumours are clearly important biomarkers of tumour progression and patient survival and also influence response to new generation EGFR antagonists, we have used a variety of experimental approaches to further investigate inter-individual differences in K-Ras mutation burden.	K-Ras	tumour	0.0
55	K-Ras was amplified from genomic DNA extracted from normal and tumour tissues (n=96 normal/tumour pairs) from our colorectal patient series (Smith et al, 2002) with the oligonucleotide primers 5'-TTTAATACTTTTTATGTATTTCAGGGTGTTG-3' (300 nM) and 5'-TTACCATCTTTGCTCATCTTTTCTTTAT-3' (300 nM) and Taqman probe 5'-FAM-TGATGCCTTCTATACATTAGTTCGAGAAATTCGAAAA-TAMRA-3' (100 nM), and expression compared with RNAse P by the comparative Ct method, according to the manufacturer's instructions (Applied Biosystems, Warrington, UK).	K-Ras	tumour	1.0
56	K-Ras was amplified from genomic DNA extracted from normal and tumour tissues (n=96 normal/tumour pairs) from our colorectal patient series (Smith et al, 2002) with the oligonucleotide primers 5'-TTTAATACTTTTTATGTATTTCAGGGTGTTG-3' (300 nM) and 5'-TTACCATCTTTGCTCATCTTTTCTTTAT-3' (300 nM) and Taqman probe 5'-FAM-TGATGCCTTCTATACATTAGTTCGAGAAATTCGAAAA-TAMRA-3' (100 nM), and expression compared with RNAse P by the comparative Ct method, according to the manufacturer's instructions (Applied Biosystems, Warrington, UK).	K-Ras	tumour	1.0
57	K-Ras was amplified from genomic DNA extracted from normal and tumour tissues (n=96 normal/tumour pairs) from our colorectal patient series (Smith et al, 2002) with the oligonucleotide primers 5'-TTTAATACTTTTTATGTATTTCAGGGTGTTG-3' (300 nM) and 5'-TTACCATCTTTGCTCATCTTTTCTTTAT-3' (300 nM) and Taqman probe 5'-FAM-TGATGCCTTCTATACATTAGTTCGAGAAATTCGAAAA-TAMRA-3' (100 nM), and expression compared with RNAse P by the comparative Ct method, according to the manufacturer's instructions (Applied Biosystems, Warrington, UK).	K-Ras	colorectal	1.0
58	Meanwhile, 1 mul chromosome 12p BAC RP11-707G18 (Red) (BlueGnome), 1 mul chromosome 12q BAC RP11-89H19 (Green) (BlueGnome) and 9 mul LSI-WCP hybridisation buffer (Vysis) was mixed together for each slide and pipetted onto a 22 x 22 mm coverslip which was placed onto a region of the slide containing tumour tissue and placed onto a heat block at 75 C for 5 min to co-denature the probes and tumour tissue	RP11	tumour	1.0
59	Meanwhile, 1 mul chromosome 12p BAC RP11-707G18 (Red) (BlueGnome), 1 mul chromosome 12q BAC RP11-89H19 (Green) (BlueGnome) and 9 mul LSI-WCP hybridisation buffer (Vysis) was mixed together for each slide and pipetted onto a 22 x 22 mm coverslip which was placed onto a region of the slide containing tumour tissue and placed onto a heat block at 75 C for 5 min to co-denature the probes and tumour tissue	RP11	tumour	1.0
60	Meanwhile, 1 mul chromosome 12p BAC RP11-707G18 (Red) (BlueGnome), 1 mul chromosome 12q BAC RP11-89H19 (Green) (BlueGnome) and 9 mul LSI-WCP hybridisation buffer (Vysis) was mixed together for each slide and pipetted onto a 22 x 22 mm coverslip which was placed onto a region of the slide containing tumour tissue and placed onto a heat block at 75 C for 5 min to co-denature the probes and tumour tissue	RP11	tumour	1.0
61	Meanwhile, 1 mul chromosome 12p BAC RP11-707G18 (Red) (BlueGnome), 1 mul chromosome 12q BAC RP11-89H19 (Green) (BlueGnome) and 9 mul LSI-WCP hybridisation buffer (Vysis) was mixed together for each slide and pipetted onto a 22 x 22 mm coverslip which was placed onto a region of the slide containing tumour tissue and placed onto a heat block at 75 C for 5 min to co-denature the probes and tumour tissue	RP11	tumour	1.0
62	We have previously described K-Ras mutations at codons 12, 13 and 61 in a series of 106 unselected colorectal tumours (Smith et al, 2002)	K-Ras	colorectal tumours	0.0
63	Mutations at codon 19 (G57T, Leu19Phe) and in B-Raf (V600E) were found in single tumours (Table 2).	B-Raf	tumours	1.0
64	To identify additional K-Ras mutations, and to establish the relative frequencies of individual K-Ras mutations in human colorectal tumours, we used WAVE analysis followed by direct sequencing to screen the same tumour series for mutations in K-Ras exon 3 and exon 4B, the most common exon 4 splice variant	K-Ras	colorectal tumours	1.0
65	To identify additional K-Ras mutations, and to establish the relative frequencies of individual K-Ras mutations in human colorectal tumours, we used WAVE analysis followed by direct sequencing to screen the same tumour series for mutations in K-Ras exon 3 and exon 4B, the most common exon 4 splice variant	K-Ras	tumour	1.0
66	To identify additional K-Ras mutations, and to establish the relative frequencies of individual K-Ras mutations in human colorectal tumours, we used WAVE analysis followed by direct sequencing to screen the same tumour series for mutations in K-Ras exon 3 and exon 4B, the most common exon 4 splice variant	K-Ras	colorectal tumours	1.0
67	To identify additional K-Ras mutations, and to establish the relative frequencies of individual K-Ras mutations in human colorectal tumours, we used WAVE analysis followed by direct sequencing to screen the same tumour series for mutations in K-Ras exon 3 and exon 4B, the most common exon 4 splice variant	K-Ras	tumour	1.0
68	To identify additional K-Ras mutations, and to establish the relative frequencies of individual K-Ras mutations in human colorectal tumours, we used WAVE analysis followed by direct sequencing to screen the same tumour series for mutations in K-Ras exon 3 and exon 4B, the most common exon 4 splice variant	K-Ras	colorectal tumours	1.0
69	To identify additional K-Ras mutations, and to establish the relative frequencies of individual K-Ras mutations in human colorectal tumours, we used WAVE analysis followed by direct sequencing to screen the same tumour series for mutations in K-Ras exon 3 and exon 4B, the most common exon 4 splice variant	K-Ras	tumour	1.0
70	To determine the frequencies of the codon 117, 146 and 164 K-Ras mutations and the codon 173 SNP, PCR-RFLP assays were designed to permit rapid screening of blood and tumour DNA (Appendix A)	K-Ras	tumour	1.0
71	No tumours with codon 19, 117, 146 or 146 mutations had additional K-Ras mutations in codons 12, 13 or 61	K-Ras	tumours	1.0
72	To investigate whether altered K-Ras activity could additionally result from gene amplification, a K-Ras gene copy number assay was designed and carried out as described in Materials and Methods and K-Ras copy number compared in normal and tumour tissues	K-Ras	tumour	1.0
73	To investigate whether altered K-Ras activity could additionally result from gene amplification, a K-Ras gene copy number assay was designed and carried out as described in Materials and Methods and K-Ras copy number compared in normal and tumour tissues	K-Ras	tumour	1.0
74	To investigate whether altered K-Ras activity could additionally result from gene amplification, a K-Ras gene copy number assay was designed and carried out as described in Materials and Methods and K-Ras copy number compared in normal and tumour tissues	K-Ras	tumour	1.0
75	In total, 2 of the 96 tumour pairs analysed (2.1%) showed tumour-specific copy number increases (Figure 6), one (study code 1264, wt K-Ras) with 4 tumour copies of K-Ras and the other (study code 1233, wt K-Ras) with 27 copies of the K-Ras gene	K-Ras	tumour	1.0
76	In total, 2 of the 96 tumour pairs analysed (2.1%) showed tumour-specific copy number increases (Figure 6), one (study code 1264, wt K-Ras) with 4 tumour copies of K-Ras and the other (study code 1233, wt K-Ras) with 27 copies of the K-Ras gene	K-Ras	tumour	1.0
77	In total, 2 of the 96 tumour pairs analysed (2.1%) showed tumour-specific copy number increases (Figure 6), one (study code 1264, wt K-Ras) with 4 tumour copies of K-Ras and the other (study code 1233, wt K-Ras) with 27 copies of the K-Ras gene	K-Ras	tumour	1.0
78	In total, 2 of the 96 tumour pairs analysed (2.1%) showed tumour-specific copy number increases (Figure 6), one (study code 1264, wt K-Ras) with 4 tumour copies of K-Ras and the other (study code 1233, wt K-Ras) with 27 copies of the K-Ras gene	K-Ras	tumour	1.0
79	In total, 2 of the 96 tumour pairs analysed (2.1%) showed tumour-specific copy number increases (Figure 6), one (study code 1264, wt K-Ras) with 4 tumour copies of K-Ras and the other (study code 1233, wt K-Ras) with 27 copies of the K-Ras gene	K-Ras	tumour	1.0
80	In total, 2 of the 96 tumour pairs analysed (2.1%) showed tumour-specific copy number increases (Figure 6), one (study code 1264, wt K-Ras) with 4 tumour copies of K-Ras and the other (study code 1233, wt K-Ras) with 27 copies of the K-Ras gene	K-Ras	tumour	1.0
81	In total, 2 of the 96 tumour pairs analysed (2.1%) showed tumour-specific copy number increases (Figure 6), one (study code 1264, wt K-Ras) with 4 tumour copies of K-Ras and the other (study code 1233, wt K-Ras) with 27 copies of the K-Ras gene	K-Ras	tumour	1.0
82	In total, 2 of the 96 tumour pairs analysed (2.1%) showed tumour-specific copy number increases (Figure 6), one (study code 1264, wt K-Ras) with 4 tumour copies of K-Ras and the other (study code 1233, wt K-Ras) with 27 copies of the K-Ras gene	K-Ras	tumour	1.0
83	In total, 2 of the 96 tumour pairs analysed (2.1%) showed tumour-specific copy number increases (Figure 6), one (study code 1264, wt K-Ras) with 4 tumour copies of K-Ras and the other (study code 1233, wt K-Ras) with 27 copies of the K-Ras gene	K-Ras	tumour	1.0
84	In total, 2 of the 96 tumour pairs analysed (2.1%) showed tumour-specific copy number increases (Figure 6), one (study code 1264, wt K-Ras) with 4 tumour copies of K-Ras and the other (study code 1233, wt K-Ras) with 27 copies of the K-Ras gene	K-Ras	tumour	1.0
85	In total, 2 of the 96 tumour pairs analysed (2.1%) showed tumour-specific copy number increases (Figure 6), one (study code 1264, wt K-Ras) with 4 tumour copies of K-Ras and the other (study code 1233, wt K-Ras) with 27 copies of the K-Ras gene	K-Ras	tumour	1.0
86	In total, 2 of the 96 tumour pairs analysed (2.1%) showed tumour-specific copy number increases (Figure 6), one (study code 1264, wt K-Ras) with 4 tumour copies of K-Ras and the other (study code 1233, wt K-Ras) with 27 copies of the K-Ras gene	K-Ras	tumour	1.0
87	Figure 7C illustrates a tumour sample (study code 1271) in which the K-Ras gene is not amplified (red fluorescence=green fluorescence), whereas Figure 7D illustrates a colorectal tumour (study code 1264) with K-Ras gene amplification (red fluorescence>green fluorescence)	K-Ras	tumour	1.0
88	Figure 7C illustrates a tumour sample (study code 1271) in which the K-Ras gene is not amplified (red fluorescence=green fluorescence), whereas Figure 7D illustrates a colorectal tumour (study code 1264) with K-Ras gene amplification (red fluorescence>green fluorescence)	K-Ras	tumour	1.0
89	Figure 7C illustrates a tumour sample (study code 1271) in which the K-Ras gene is not amplified (red fluorescence=green fluorescence), whereas Figure 7D illustrates a colorectal tumour (study code 1264) with K-Ras gene amplification (red fluorescence>green fluorescence)	K-Ras	colorectal tumour	1.0
90	Figure 7C illustrates a tumour sample (study code 1271) in which the K-Ras gene is not amplified (red fluorescence=green fluorescence), whereas Figure 7D illustrates a colorectal tumour (study code 1264) with K-Ras gene amplification (red fluorescence>green fluorescence)	K-Ras	colorectal tumour	1.0
91	Recent clinical data has shown a compelling association between K-Ras and B-Raf mutation status and response to EGFR blockade by cetuximab and panitumumab in the treatment of metastatic colorectal tumours (Benvenuti et al, 2007; Khambata-Ford et al, 2007; Freeman et al, 2008; Karapetis et al, 2008; Ramos et al, 2008)	K-Ras	colorectal tumours	0.0
92	Recent clinical data has shown a compelling association between K-Ras and B-Raf mutation status and response to EGFR blockade by cetuximab and panitumumab in the treatment of metastatic colorectal tumours (Benvenuti et al, 2007; Khambata-Ford et al, 2007; Freeman et al, 2008; Karapetis et al, 2008; Ramos et al, 2008)	B-Raf	colorectal tumours	0.0
93	Recent clinical data has shown a compelling association between K-Ras and B-Raf mutation status and response to EGFR blockade by cetuximab and panitumumab in the treatment of metastatic colorectal tumours (Benvenuti et al, 2007; Khambata-Ford et al, 2007; Freeman et al, 2008; Karapetis et al, 2008; Ramos et al, 2008)	EGFR	colorectal tumours	0.0
94	K-Ras mutations in colorectal tumours have been extensively documented, where recent meta analysis of more than 3000 tumours estimates an average K-Ras mutation frequency of 34.8% (Andreyev et al, 2001)	K-Ras	colorectal tumours	0.0
95	K-Ras mutations in colorectal tumours have been extensively documented, where recent meta analysis of more than 3000 tumours estimates an average K-Ras mutation frequency of 34.8% (Andreyev et al, 2001)	K-Ras	tumours	0.0
96	K-Ras mutations in colorectal tumours have been extensively documented, where recent meta analysis of more than 3000 tumours estimates an average K-Ras mutation frequency of 34.8% (Andreyev et al, 2001)	K-Ras	colorectal tumours	0.0
97	K-Ras mutations in colorectal tumours have been extensively documented, where recent meta analysis of more than 3000 tumours estimates an average K-Ras mutation frequency of 34.8% (Andreyev et al, 2001)	K-Ras	tumours	0.0
98	Although additional K-Ras mutations have been reported outwith these 'hotspot' codons, to our knowledge, there has been no systematic analysis of K-Ras mutation frequency in human colorectal tumours	K-Ras	colorectal tumours	0.0
99	Although additional K-Ras mutations have been reported outwith these 'hotspot' codons, to our knowledge, there has been no systematic analysis of K-Ras mutation frequency in human colorectal tumours	K-Ras	colorectal tumours	0.0
100	Our use of 'WAVE' denaturing HPLC (dHPLC) analysis (Kuklin et al, 1997) allowed us to carry out a rapid, systematic analysis of the entire K-Ras coding sequence to identify colorectal tumours with sequence changes, the nature which were subsequently confirmed by conventional dideoxy sequencing.	K-Ras	colorectal tumours	1.0
101	Our data clearly demonstrates that K-Ras mutations in human colorectal tumours are likely to be significantly underestimated if only hotspot codons are analysed	K-Ras	colorectal tumours	1.0
102	Current data from the COSMIC database, which summarises literature data and the ongoing Sanger cancer-genome project describes 29 K-Ras colorectal tumour mutations outwith codons 12, 13 and 61, and more than 11 800 mutations at these hotspot codons (http://www.sanger.ac.uk/genetics/CGP/), but does not describe associated phenotypes	K-Ras	cancer	1.0
103	Current data from the COSMIC database, which summarises literature data and the ongoing Sanger cancer-genome project describes 29 K-Ras colorectal tumour mutations outwith codons 12, 13 and 61, and more than 11 800 mutations at these hotspot codons (http://www.sanger.ac.uk/genetics/CGP/), but does not describe associated phenotypes	K-Ras	colorectal tumour	1.0
104	K-Ras codon 146 mutations have been described in a human colorectal tumour cell line (Higashi et al, 1990), in mice with thymic lymphomas (Sloan et al, 1990) and in a single human colorectal tumour case report (Orita et al, 1991)	K-Ras	colorectal tumour	0.0
105	K-Ras codon 146 mutations have been described in a human colorectal tumour cell line (Higashi et al, 1990), in mice with thymic lymphomas (Sloan et al, 1990) and in a single human colorectal tumour case report (Orita et al, 1991)	K-Ras	thymic lymphomas	0.0
106	K-Ras codon 146 mutations have been described in a human colorectal tumour cell line (Higashi et al, 1990), in mice with thymic lymphomas (Sloan et al, 1990) and in a single human colorectal tumour case report (Orita et al, 1991)	K-Ras	colorectal tumour	0.0
107	Consistent with our own data, Tyner et al (2009) reported an oncogenic phenotype associated with the K-Ras 146 mutation in leukaemia and Loupakis et al (2009) have recently reported that a patient with metastatic colorectal cancer with a K-Ras 146 mutation was resistant to cetuximab.	K-Ras	leukaemia	1.0
108	Consistent with our own data, Tyner et al (2009) reported an oncogenic phenotype associated with the K-Ras 146 mutation in leukaemia and Loupakis et al (2009) have recently reported that a patient with metastatic colorectal cancer with a K-Ras 146 mutation was resistant to cetuximab.	K-Ras	colorectal cancer	1.0
109	Consistent with our own data, Tyner et al (2009) reported an oncogenic phenotype associated with the K-Ras 146 mutation in leukaemia and Loupakis et al (2009) have recently reported that a patient with metastatic colorectal cancer with a K-Ras 146 mutation was resistant to cetuximab.	K-Ras	leukaemia	1.0
110	Consistent with our own data, Tyner et al (2009) reported an oncogenic phenotype associated with the K-Ras 146 mutation in leukaemia and Loupakis et al (2009) have recently reported that a patient with metastatic colorectal cancer with a K-Ras 146 mutation was resistant to cetuximab.	K-Ras	colorectal cancer	1.0
111	There is only a single report of K-Ras codon 19 mutations in human colorectal tumours (Akagi et al, 2007), in which in vitro elevation of active Ras-GTP levels, anchorage-independent growth and increased tumourigenicity in nude mice was demonstrated	K-Ras	colorectal tumours	1.0
112	A codon 19 mutation has additionally been described in H-Ras in a human pituitary carcinoma metastases (Pei et al, 1994)	H-Ras	pituitary carcinoma metastases	1.0
113	There are two recent reports of codon 117 mutations - the first in K-Ras in human colorectal tumours (Wojcik et al, 2008) and the second in H-Ras, associated with activation of the RAS-MAPK pathway and the mental retardation Costello syndrome (Denayer et al, 2008)	K-Ras	colorectal tumours	0.0
114	There are two recent reports of codon 117 mutations - the first in K-Ras in human colorectal tumours (Wojcik et al, 2008) and the second in H-Ras, associated with activation of the RAS-MAPK pathway and the mental retardation Costello syndrome (Denayer et al, 2008)	K-Ras	mental retardation Costello syndrome	0.0
115	There are two recent reports of codon 117 mutations - the first in K-Ras in human colorectal tumours (Wojcik et al, 2008) and the second in H-Ras, associated with activation of the RAS-MAPK pathway and the mental retardation Costello syndrome (Denayer et al, 2008)	H-Ras	colorectal tumours	0.0
116	There are two recent reports of codon 117 mutations - the first in K-Ras in human colorectal tumours (Wojcik et al, 2008) and the second in H-Ras, associated with activation of the RAS-MAPK pathway and the mental retardation Costello syndrome (Denayer et al, 2008)	MAPK	colorectal tumours	0.0
117	There are two recent reports of codon 117 mutations - the first in K-Ras in human colorectal tumours (Wojcik et al, 2008) and the second in H-Ras, associated with activation of the RAS-MAPK pathway and the mental retardation Costello syndrome (Denayer et al, 2008)	H-Ras	mental retardation Costello syndrome	0.0
118	There are two recent reports of codon 117 mutations - the first in K-Ras in human colorectal tumours (Wojcik et al, 2008) and the second in H-Ras, associated with activation of the RAS-MAPK pathway and the mental retardation Costello syndrome (Denayer et al, 2008)	MAPK	mental retardation Costello syndrome	0.0
119	There are no reports of K-Ras 164 mutations, and mutations at this codon were not identified by Sanger cancer genome project investigators.	K-Ras	cancer	1.0
120	Recent clinical data convincingly associates response to anti-EGFR therapies with K-Ras mutation status in patients with metastatic colorectal cancer where, logically, response is preferentially observed in K-Ras wt tumours (Lievre et al, 2006; Benvenuti et al, 2007; Khambata-Ford et al, 2007; Freeman et al, 2008; Karapetis et al, 2008; Ramos et al, 2008; Loupakis et al, 2009; Van Cutsem et al, 2009) which retain the ability to respond to EGFR blockade	EGFR	colorectal cancer	1.0
121	Recent clinical data convincingly associates response to anti-EGFR therapies with K-Ras mutation status in patients with metastatic colorectal cancer where, logically, response is preferentially observed in K-Ras wt tumours (Lievre et al, 2006; Benvenuti et al, 2007; Khambata-Ford et al, 2007; Freeman et al, 2008; Karapetis et al, 2008; Ramos et al, 2008; Loupakis et al, 2009; Van Cutsem et al, 2009) which retain the ability to respond to EGFR blockade	EGFR	K-Ras wt tumours	1.0
122	Recent clinical data convincingly associates response to anti-EGFR therapies with K-Ras mutation status in patients with metastatic colorectal cancer where, logically, response is preferentially observed in K-Ras wt tumours (Lievre et al, 2006; Benvenuti et al, 2007; Khambata-Ford et al, 2007; Freeman et al, 2008; Karapetis et al, 2008; Ramos et al, 2008; Loupakis et al, 2009; Van Cutsem et al, 2009) which retain the ability to respond to EGFR blockade	K-Ras	colorectal cancer	1.0
123	Recent clinical data convincingly associates response to anti-EGFR therapies with K-Ras mutation status in patients with metastatic colorectal cancer where, logically, response is preferentially observed in K-Ras wt tumours (Lievre et al, 2006; Benvenuti et al, 2007; Khambata-Ford et al, 2007; Freeman et al, 2008; Karapetis et al, 2008; Ramos et al, 2008; Loupakis et al, 2009; Van Cutsem et al, 2009) which retain the ability to respond to EGFR blockade	K-Ras	K-Ras wt tumours	1.0
124	Recent clinical data convincingly associates response to anti-EGFR therapies with K-Ras mutation status in patients with metastatic colorectal cancer where, logically, response is preferentially observed in K-Ras wt tumours (Lievre et al, 2006; Benvenuti et al, 2007; Khambata-Ford et al, 2007; Freeman et al, 2008; Karapetis et al, 2008; Ramos et al, 2008; Loupakis et al, 2009; Van Cutsem et al, 2009) which retain the ability to respond to EGFR blockade	EGFR	colorectal cancer	0.0
125	Recent clinical data convincingly associates response to anti-EGFR therapies with K-Ras mutation status in patients with metastatic colorectal cancer where, logically, response is preferentially observed in K-Ras wt tumours (Lievre et al, 2006; Benvenuti et al, 2007; Khambata-Ford et al, 2007; Freeman et al, 2008; Karapetis et al, 2008; Ramos et al, 2008; Loupakis et al, 2009; Van Cutsem et al, 2009) which retain the ability to respond to EGFR blockade	EGFR	K-Ras wt tumours	1.0
126	Our description of K-Ras gene amplification in a subset of wt tumours is of particular interest in this regard as increased K-Ras gene copy number may lead to a more active 'mutation'-like phenotype	K-Ras	tumours	1.0
127	Our description of K-Ras gene amplification in a subset of wt tumours is of particular interest in this regard as increased K-Ras gene copy number may lead to a more active 'mutation'-like phenotype	K-Ras	tumours	1.0
128	Consistent with our own data, DUSP4 expression has previously been shown to be increased in pancreatic tumours with K-Ras mutations (Yip-Schneider et al, 2001) and DUSP6 expression increased in a variety of tumour types with mutations in Ras or Raf pathway genes (Croonquist et al, 2003; Warmka et al, 2004; Bloethner et al, 2005)	DUSP4	pancreatic tumours	0.0
129	Consistent with our own data, DUSP4 expression has previously been shown to be increased in pancreatic tumours with K-Ras mutations (Yip-Schneider et al, 2001) and DUSP6 expression increased in a variety of tumour types with mutations in Ras or Raf pathway genes (Croonquist et al, 2003; Warmka et al, 2004; Bloethner et al, 2005)	DUSP4	tumour	0.0
130	Consistent with our own data, DUSP4 expression has previously been shown to be increased in pancreatic tumours with K-Ras mutations (Yip-Schneider et al, 2001) and DUSP6 expression increased in a variety of tumour types with mutations in Ras or Raf pathway genes (Croonquist et al, 2003; Warmka et al, 2004; Bloethner et al, 2005)	K-Ras	pancreatic tumours	0.0
131	Consistent with our own data, DUSP4 expression has previously been shown to be increased in pancreatic tumours with K-Ras mutations (Yip-Schneider et al, 2001) and DUSP6 expression increased in a variety of tumour types with mutations in Ras or Raf pathway genes (Croonquist et al, 2003; Warmka et al, 2004; Bloethner et al, 2005)	DUSP6	pancreatic tumours	0.0
132	Consistent with our own data, DUSP4 expression has previously been shown to be increased in pancreatic tumours with K-Ras mutations (Yip-Schneider et al, 2001) and DUSP6 expression increased in a variety of tumour types with mutations in Ras or Raf pathway genes (Croonquist et al, 2003; Warmka et al, 2004; Bloethner et al, 2005)	Raf	pancreatic tumours	0.0
133	Consistent with our own data, DUSP4 expression has previously been shown to be increased in pancreatic tumours with K-Ras mutations (Yip-Schneider et al, 2001) and DUSP6 expression increased in a variety of tumour types with mutations in Ras or Raf pathway genes (Croonquist et al, 2003; Warmka et al, 2004; Bloethner et al, 2005)	K-Ras	tumour	0.0
134	Consistent with our own data, DUSP4 expression has previously been shown to be increased in pancreatic tumours with K-Ras mutations (Yip-Schneider et al, 2001) and DUSP6 expression increased in a variety of tumour types with mutations in Ras or Raf pathway genes (Croonquist et al, 2003; Warmka et al, 2004; Bloethner et al, 2005)	DUSP6	tumour	0.0
135	Consistent with our own data, DUSP4 expression has previously been shown to be increased in pancreatic tumours with K-Ras mutations (Yip-Schneider et al, 2001) and DUSP6 expression increased in a variety of tumour types with mutations in Ras or Raf pathway genes (Croonquist et al, 2003; Warmka et al, 2004; Bloethner et al, 2005)	Raf	tumour	0.0
136	Of particular interest, however, was our observation that certain signalling cascades, including those mediated by Igf1 and Vegf, were differentially activated by cluster 1 and cluster 2 K-Ras mutants, suggesting that not only the presence but the specific molecular characteristics of individual K-Ras mutations may be important determinants of both tumour progression and treatment response	Igf1	tumour	1.0
137	Of particular interest, however, was our observation that certain signalling cascades, including those mediated by Igf1 and Vegf, were differentially activated by cluster 1 and cluster 2 K-Ras mutants, suggesting that not only the presence but the specific molecular characteristics of individual K-Ras mutations may be important determinants of both tumour progression and treatment response	Vegf	tumour	1.0
138	Of particular interest, however, was our observation that certain signalling cascades, including those mediated by Igf1 and Vegf, were differentially activated by cluster 1 and cluster 2 K-Ras mutants, suggesting that not only the presence but the specific molecular characteristics of individual K-Ras mutations may be important determinants of both tumour progression and treatment response	K-Ras	tumour	1.0
139	Of particular interest, however, was our observation that certain signalling cascades, including those mediated by Igf1 and Vegf, were differentially activated by cluster 1 and cluster 2 K-Ras mutants, suggesting that not only the presence but the specific molecular characteristics of individual K-Ras mutations may be important determinants of both tumour progression and treatment response	K-Ras	tumour	1.0
140	For example, recent data suggests that glucose deprivation can promote the acquisition of K-Ras mutations in human tumours and reports upregulation of the glucose transporter GLUT-1 in K-Ras mutant tumours (Yun et al, 2009)	K-Ras	glucose deprivation	1.0
141	For example, recent data suggests that glucose deprivation can promote the acquisition of K-Ras mutations in human tumours and reports upregulation of the glucose transporter GLUT-1 in K-Ras mutant tumours (Yun et al, 2009)	GLUT-1	glucose deprivation	1.0
142	For example, recent data suggests that glucose deprivation can promote the acquisition of K-Ras mutations in human tumours and reports upregulation of the glucose transporter GLUT-1 in K-Ras mutant tumours (Yun et al, 2009)	K-Ras	glucose deprivation	1.0
143	For example, recent data suggests that glucose deprivation can promote the acquisition of K-Ras mutations in human tumours and reports upregulation of the glucose transporter GLUT-1 in K-Ras mutant tumours (Yun et al, 2009)	K-Ras	tumours	1.0
144	For example, recent data suggests that glucose deprivation can promote the acquisition of K-Ras mutations in human tumours and reports upregulation of the glucose transporter GLUT-1 in K-Ras mutant tumours (Yun et al, 2009)	K-Ras	tumours	1.0
145	For example, recent data suggests that glucose deprivation can promote the acquisition of K-Ras mutations in human tumours and reports upregulation of the glucose transporter GLUT-1 in K-Ras mutant tumours (Yun et al, 2009)	GLUT-1	tumours	1.0
146	For example, recent data suggests that glucose deprivation can promote the acquisition of K-Ras mutations in human tumours and reports upregulation of the glucose transporter GLUT-1 in K-Ras mutant tumours (Yun et al, 2009)	K-Ras	tumours	1.0
147	For example, recent data suggests that glucose deprivation can promote the acquisition of K-Ras mutations in human tumours and reports upregulation of the glucose transporter GLUT-1 in K-Ras mutant tumours (Yun et al, 2009)	GLUT-1	tumours	1.0
148	For example, recent data suggests that glucose deprivation can promote the acquisition of K-Ras mutations in human tumours and reports upregulation of the glucose transporter GLUT-1 in K-Ras mutant tumours (Yun et al, 2009)	K-Ras	tumours	1.0
149	Current clinical data is sufficiently compelling that K-Ras mutation testing to facilitate the selection of patients most likely to benefit from anti-EGFR therapy is increasingly recommended in clinical practise (McNeill, 2008; van Krieken and Tol, 2009), and has resulted in a recent formal recommendation from the National Comprehensive Cancer Network that patients with K-Ras tumour mutations should not be treated with cetuximab or panitumumab (McNeill, 2008)	K-Ras	van Krieken	0.0
150	Current clinical data is sufficiently compelling that K-Ras mutation testing to facilitate the selection of patients most likely to benefit from anti-EGFR therapy is increasingly recommended in clinical practise (McNeill, 2008; van Krieken and Tol, 2009), and has resulted in a recent formal recommendation from the National Comprehensive Cancer Network that patients with K-Ras tumour mutations should not be treated with cetuximab or panitumumab (McNeill, 2008)	K-Ras	K-Ras tumour	0.0
151	Current clinical data is sufficiently compelling that K-Ras mutation testing to facilitate the selection of patients most likely to benefit from anti-EGFR therapy is increasingly recommended in clinical practise (McNeill, 2008; van Krieken and Tol, 2009), and has resulted in a recent formal recommendation from the National Comprehensive Cancer Network that patients with K-Ras tumour mutations should not be treated with cetuximab or panitumumab (McNeill, 2008)	EGFR	van Krieken	0.0
152	Current clinical data is sufficiently compelling that K-Ras mutation testing to facilitate the selection of patients most likely to benefit from anti-EGFR therapy is increasingly recommended in clinical practise (McNeill, 2008; van Krieken and Tol, 2009), and has resulted in a recent formal recommendation from the National Comprehensive Cancer Network that patients with K-Ras tumour mutations should not be treated with cetuximab or panitumumab (McNeill, 2008)	EGFR	K-Ras tumour	0.0
153	Although the clinical implications of non-hotspot K-Ras mutations requires further validation both as prognostic markers and therapeutic targets, our data suggests that future analysis of K-Ras mutations and quantitation of mutation burden in colorectal tumours should not be limited to previously described mutation hotspots and should additionally consider the unique molecular signatures associated with individual K-Ras mutations.	K-Ras	colorectal tumours	1.0
154	Although the clinical implications of non-hotspot K-Ras mutations requires further validation both as prognostic markers and therapeutic targets, our data suggests that future analysis of K-Ras mutations and quantitation of mutation burden in colorectal tumours should not be limited to previously described mutation hotspots and should additionally consider the unique molecular signatures associated with individual K-Ras mutations.	K-Ras	colorectal tumours	1.0
155	Although the clinical implications of non-hotspot K-Ras mutations requires further validation both as prognostic markers and therapeutic targets, our data suggests that future analysis of K-Ras mutations and quantitation of mutation burden in colorectal tumours should not be limited to previously described mutation hotspots and should additionally consider the unique molecular signatures associated with individual K-Ras mutations.	K-Ras	colorectal tumours	1.0
156	Characterization of a novel oncogenic K-ras mutation in colon cancer	K-ras	colon cancer	1.0
157	Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies	RAF	colorectal cancers	1.0
158	Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies	epidermal growth factor receptor	colorectal cancers	1.0
159	Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines	B-RAF	melanoma	1.0
160	Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines	N-RAS	melanoma	1.0
161	The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma	K-ras	APC	1.0
162	The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma	K-ras	colorectal carcinoma	1.0
163	The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma	p53	APC	1.0
164	The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma	p53	colorectal carcinoma	1.0
165	Gene profiling of a myeloma cell line reveals similarities and unique signatures among IL-6 response, N-ras-activating mutations, and coculture with bone marrow stromal cells	IL-6	myeloma	1.0
166	Gene profiling of a myeloma cell line reveals similarities and unique signatures among IL-6 response, N-ras-activating mutations, and coculture with bone marrow stromal cells	N-ras	myeloma	1.0
167	Mutations of the BRAF gene in human cancer	BRAF	cancer	1.0
168	Mutation analysis in Costello syndrome: functional and structural characterization of the HRAS p.Lys117Arg mutation	HRAS	Costello syndrome	1.0
169	Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer	BRAF	colorectal cancer	1.0
170	Recurrent KRAS codon 146 mutations in human colorectal cancer	KRAS	colorectal cancer	1.0
171	K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy	K-Ras	colorectal cancer	1.0
172	Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone	K-ras	colorectal cancer	1.0
173	Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes	RUNX1	chronic myelomonocytic leukemia	1.0
174	K-ras mutations and benefit from cetuximab in advanced colorectal cancer	K-ras	colorectal cancer	1.0
175	Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab	epiregulin	colorectal cancer	1.0
176	Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab	amphiregulin	colorectal cancer	1.0
177	Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab	K-ras	colorectal cancer	1.0
178	Mutations of APC, K-ras, and p53 are associated with specific chromosomal aberrations in colorectal adenocarcinomas	K-ras	APC	1.0
179	Mutations of APC, K-ras, and p53 are associated with specific chromosomal aberrations in colorectal adenocarcinomas	p53	APC	1.0
180	Mutations of APC, K-ras, and p53 are associated with specific chromosomal aberrations in colorectal adenocarcinomas	K-ras	colorectal adenocarcinomas	1.0
181	Mutations of APC, K-ras, and p53 are associated with specific chromosomal aberrations in colorectal adenocarcinomas	p53	colorectal adenocarcinomas	1.0
182	KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer	KRAS	colorectal cancer	1.0
183	KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer	KRAS	colorectal cancer	1.0
184	KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer	BRAF	colorectal cancer	1.0
185	KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer	KRAS	colorectal cancer	1.0
186	K-Ras mutations are changingpractice in advanced colorectal cancer	K-Ras	colorectal cancer	1.0
187	Concurrent mutations of K-ras oncogene at codons 12 and 22 in colon cancer	K-ras	colon cancer	1.0
188	A novel point mutation at codon 146 of the K-ras gene in a human colorectal cancer identified by the polymerase chain reaction	K-ras	colorectal cancer	1.0
189	H-ras mutations in human pituitary carcinoma metastases	H-ras	pituitary carcinoma metastases	1.0
190	Understanding the predictive role of K-ras for epidermal growth factor receptor-targeted therapies in colorectal cancer	K-ras	colorectal cancer	1.0
191	Understanding the predictive role of K-ras for epidermal growth factor receptor-targeted therapies in colorectal cancer	epidermal growth factor receptor	colorectal cancer	1.0
192	Mutations in APC, Kirsten-ras, and p53-alternative genetic pathways to colorectal cancer	Kirsten-ras	APC	1.0
193	Mutations in APC, Kirsten-ras, and p53-alternative genetic pathways to colorectal cancer	p53	APC	1.0
194	Mutations in APC, Kirsten-ras, and p53-alternative genetic pathways to colorectal cancer	Kirsten-ras	colorectal cancer	1.0
195	Mutations in APC, Kirsten-ras, and p53-alternative genetic pathways to colorectal cancer	p53	colorectal cancer	1.0
196	Setting future standards for KRAS testing in colorectal cancer	KRAS	colorectal cancer	1.0
197	Mitogen-activated protein kinase phosphatase-3 is a tumor promoter target in initiated cells that express oncogenic Ras	Mitogen-activated protein kinase phosphatase-3	tumor	1.0
198	Different types of K-Ras mutations are conversely associated with overall survival in patients with colorectal cancer	K-Ras	colorectal cancer	1.0
199	KRAS mutation profile in colorectal carcinoma and novel mutation-internal tandem duplication in KRAS	KRAS	colorectal carcinoma	1.0
200	Pancreatic tumor cells with mutant K-ras suppress ERK activity by MEK-dependent induction of MAP kinase phosphatase-2	K-ras	Pancreatic tumor	1.0
201	Pancreatic tumor cells with mutant K-ras suppress ERK activity by MEK-dependent induction of MAP kinase phosphatase-2	ERK	Pancreatic tumor	1.0
202	Pancreatic tumor cells with mutant K-ras suppress ERK activity by MEK-dependent induction of MAP kinase phosphatase-2	MEK	Pancreatic tumor	1.0
203	Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells	KRAS	Glucose deprivation	1.0
204	Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells	KRAS	tumor	1.0
205	Active Ras, where tumour-specific mutations lock Ras in the GTP-bound conformation, stimulates the RAS-RAF-MEK-ERK-MAP kinase signalling pathway.	RAF	tumour	1.0
206	Active Ras, where tumour-specific mutations lock Ras in the GTP-bound conformation, stimulates the RAS-RAF-MEK-ERK-MAP kinase signalling pathway.	MEK	tumour	1.0
207	Active Ras, where tumour-specific mutations lock Ras in the GTP-bound conformation, stimulates the RAS-RAF-MEK-ERK-MAP kinase signalling pathway.	ERK	tumour	1.0
208	A novel K-Ras gene copy number assay was designed as described in Materials and Methods and used to screen genomic DNA samples extracted from 96 paired normal (N) and colorectal tumour (T) tissues	K-Ras	colorectal tumour	1.0
209	Representative colorectal tumour sections (C) without and (D) with a K-Ras gene amplification are illustrated.	K-Ras	colorectal tumour	1.0
210	Relationship of increased aurora kinase A gene copy number, prognosis and response to chemotherapy in patients with metastatic colorectal cancer	aurora kinase A	colorectal cancer	
211	Increased Aurora kinase A gene copy number (AURKA-CN) has been reported in metastatic colorectal cancer (mCRC), with unknown relationship to clinical outcome	Aurora kinase A	colorectal cancer	
212	Increased Aurora kinase A gene copy number (AURKA-CN) has been reported in metastatic colorectal cancer (mCRC), with unknown relationship to clinical outcome	AURKA	colorectal cancer	
213	We correlated increased AURKA-CN in mCRC tumours with KRAS mutation status, overall and progression-free survival (OS, PFS).	AURKA	tumours	
214	We correlated increased AURKA-CN in mCRC tumours with KRAS mutation status, overall and progression-free survival (OS, PFS).	KRAS	tumours	
215	Sixty-one mCRC tumours were analysed for AURKA-CN using q-PCR, and KRAS mutation status by direct sequencing	AURKA	tumours	
216	Sixty-one mCRC tumours were analysed for AURKA-CN using q-PCR, and KRAS mutation status by direct sequencing	KRAS	tumours	
217	In all, 68% of tumour exhibited high AURKA-CN, and 29% had a KRAS mutation, without correlation between the two	AURKA	tumour	
218	In all, 68% of tumour exhibited high AURKA-CN, and 29% had a KRAS mutation, without correlation between the two	KRAS	tumour	
219	Patients with high AURKA-CN tumours had longer median OS (48.6 vs 18.8 months, P=0.01), with stronger trend among KRAS wild-type tumours (median OS not reached vs 18.8 months, P=0.003)	AURKA	tumours	
220	Patients with high AURKA-CN tumours had longer median OS (48.6 vs 18.8 months, P=0.01), with stronger trend among KRAS wild-type tumours (median OS not reached vs 18.8 months, P=0.003)	AURKA	tumours	
221	Patients with high AURKA-CN tumours had longer median OS (48.6 vs 18.8 months, P=0.01), with stronger trend among KRAS wild-type tumours (median OS not reached vs 18.8 months, P=0.003)	KRAS	tumours	
222	Patients with high AURKA-CN tumours had longer median OS (48.6 vs 18.8 months, P=0.01), with stronger trend among KRAS wild-type tumours (median OS not reached vs 18.8 months, P=0.003)	KRAS	tumours	
223	AURKA-CN level did not affect outcomes among patients with KRAS mutant tumours.	AURKA	tumours	
224	AURKA-CN level did not affect outcomes among patients with KRAS mutant tumours.	KRAS	tumours	
225	Increased AURKA-CN is common in mCRC tumours and is associated with longer OS and longer PFS during chemotherapy, particularly in KRAS wild-type tumours.	AURKA	tumours	
226	Increased AURKA-CN is common in mCRC tumours and is associated with longer OS and longer PFS during chemotherapy, particularly in KRAS wild-type tumours.	AURKA	tumours	
227	Increased AURKA-CN is common in mCRC tumours and is associated with longer OS and longer PFS during chemotherapy, particularly in KRAS wild-type tumours.	KRAS	tumours	
228	Increased AURKA-CN is common in mCRC tumours and is associated with longer OS and longer PFS during chemotherapy, particularly in KRAS wild-type tumours.	KRAS	tumours	
229	Aurora kinase A (AURKA) (also known as Aurora-2, BTAK/STK15) regulates mitotic entry, centrosome maturation, bipolar spindle assembly, chromosome alignment, cytokinesis and exit from mitosis	Aurora kinase A	mitosis	
230	Aurora kinase A (AURKA) (also known as Aurora-2, BTAK/STK15) regulates mitotic entry, centrosome maturation, bipolar spindle assembly, chromosome alignment, cytokinesis and exit from mitosis	AURKA	mitosis	
231	Aurora kinase A (AURKA) (also known as Aurora-2, BTAK/STK15) regulates mitotic entry, centrosome maturation, bipolar spindle assembly, chromosome alignment, cytokinesis and exit from mitosis	Aurora-2	mitosis	
232	Aurora kinase A (AURKA) (also known as Aurora-2, BTAK/STK15) regulates mitotic entry, centrosome maturation, bipolar spindle assembly, chromosome alignment, cytokinesis and exit from mitosis	BTAK	mitosis	
233	Aurora kinase A (AURKA) (also known as Aurora-2, BTAK/STK15) regulates mitotic entry, centrosome maturation, bipolar spindle assembly, chromosome alignment, cytokinesis and exit from mitosis	STK15	mitosis	
234	Aberrations in the function of Aurora kinases can result in abnormal cell division and aneuploidy due to losses or gains of whole chromosomes	Aurora kinases	aneuploidy	
235	In colorectal cancer (CRC), AURKA protein overexpression and amplification have been frequently observed	AURKA	colorectal cancer	
236	were the first to report overexpression of AURKA mRNA in >50% of CRC tumours	AURKA	CRC tumours	
237	The group led by was the first to demonstrate an increase in AURKA gene copy number (AURKA-CN) in 29% of a small sample of colorectal tumours	AURKA	colorectal tumours	
238	The group led by was the first to demonstrate an increase in AURKA gene copy number (AURKA-CN) in 29% of a small sample of colorectal tumours	AURKA	colorectal tumours	
239	Recently, the group led by reported increased AURKA-CN in 32% of CRC tumour samples and particularly in higher stage tumours, suggesting that AURKA may have a role in tumour progression	AURKA	CRC tumour	
240	Recently, the group led by reported increased AURKA-CN in 32% of CRC tumour samples and particularly in higher stage tumours, suggesting that AURKA may have a role in tumour progression	AURKA	stage tumours	
241	Recently, the group led by reported increased AURKA-CN in 32% of CRC tumour samples and particularly in higher stage tumours, suggesting that AURKA may have a role in tumour progression	AURKA	tumour	
242	Recently, the group led by reported increased AURKA-CN in 32% of CRC tumour samples and particularly in higher stage tumours, suggesting that AURKA may have a role in tumour progression	AURKA	CRC tumour	
243	Recently, the group led by reported increased AURKA-CN in 32% of CRC tumour samples and particularly in higher stage tumours, suggesting that AURKA may have a role in tumour progression	AURKA	stage tumours	
244	Recently, the group led by reported increased AURKA-CN in 32% of CRC tumour samples and particularly in higher stage tumours, suggesting that AURKA may have a role in tumour progression	AURKA	tumour	
245	The goal in this study was to assess the frequency of increased AURKA-CN in archival tumour tissues of patients with metastatic CRC (mCRC) and correlate this finding with progression-free survival (PFS), overall survival (OS), and KRAS mutation status.	AURKA	archival tumour	
246	The goal in this study was to assess the frequency of increased AURKA-CN in archival tumour tissues of patients with metastatic CRC (mCRC) and correlate this finding with progression-free survival (PFS), overall survival (OS), and KRAS mutation status.	KRAS	archival tumour	
247	We analysed 61 consecutive mCRC tumour samples submitted between 2006 and 2009 to the Fox Chase Cancer Center (FCCC) molecular genetic facility for evaluation of KRAS mutation status, with remaining tissue available for AURKA-CN evaluation	KRAS	tumour	
248	We analysed 61 consecutive mCRC tumour samples submitted between 2006 and 2009 to the Fox Chase Cancer Center (FCCC) molecular genetic facility for evaluation of KRAS mutation status, with remaining tissue available for AURKA-CN evaluation	AURKA	tumour	
249	We analysed 61 consecutive mCRC tumour samples submitted between 2006 and 2009 to the Fox Chase Cancer Center (FCCC) molecular genetic facility for evaluation of KRAS mutation status, with remaining tissue available for AURKA-CN evaluation	KRAS	Cancer	
250	We analysed 61 consecutive mCRC tumour samples submitted between 2006 and 2009 to the Fox Chase Cancer Center (FCCC) molecular genetic facility for evaluation of KRAS mutation status, with remaining tissue available for AURKA-CN evaluation	AURKA	Cancer	
251	Most of the patients had their tumour samples submitted by their treating oncologist for KRAS mutation status evaluation after the test became routinely used in clinical practice (2008)	KRAS	tumour	
252	Of the 61 tissue samples obtained for AURKA-CN analysis, 62% originated from primary tumours, while 38% originated from metastatic sites	AURKA	tumours	
253	For patients with high AURKA-CN tumours, the median PFS on first-line chemotherapy was 11.5 months vs 7.7 months for patients with low AURKA-CN tumours (HR=0.56, 95% CI: 0.28-1.1, P=0.094; Figure 3A)	AURKA	tumours	
254	For patients with high AURKA-CN tumours, the median PFS on first-line chemotherapy was 11.5 months vs 7.7 months for patients with low AURKA-CN tumours (HR=0.56, 95% CI: 0.28-1.1, P=0.094; Figure 3A)	AURKA	low AURKA-CN tumours	
255	Among patients with KRAS wild-type tumours, those with high AURKA-CN tumours had prolonged PFS compared with patients with low AURKA-CN tumours (HR=0.43, 95% CI: 0.19-0.94, P=0.04; Figure 3B)	AURKA	KRAS wild-type tumours	
256	Among patients with KRAS wild-type tumours, those with high AURKA-CN tumours had prolonged PFS compared with patients with low AURKA-CN tumours (HR=0.43, 95% CI: 0.19-0.94, P=0.04; Figure 3B)	AURKA	tumours	
257	Among patients with KRAS wild-type tumours, those with high AURKA-CN tumours had prolonged PFS compared with patients with low AURKA-CN tumours (HR=0.43, 95% CI: 0.19-0.94, P=0.04; Figure 3B)	AURKA	low AURKA-CN tumours	
258	Conversely, PFS did not differ by AURKA-CN expression among patients with KRAS mutant tumours (HR=1.06, 95% CI: 0.28-3.93, P=0.93), although the small sample size limits definitive conclusions regarding this population.	AURKA	tumours	
259	Conversely, PFS did not differ by AURKA-CN expression among patients with KRAS mutant tumours (HR=1.06, 95% CI: 0.28-3.93, P=0.93), although the small sample size limits definitive conclusions regarding this population.	KRAS	tumours	
260	No statistically significant difference in PFS was noted among patients with high vs low AURKA-CN tumours in the group overall (10.4 months vs 7.7 months; HR=0.54, 95% CI: 0.24-1.19, P=0.13; Figure 3C)	AURKA	tumours	
261	Table 3 outlines median PFS and HRs for high and low AURKA-CN tumours by KRAS mutational status and the use of cetuximab	AURKA	tumours	
262	Table 3 outlines median PFS and HRs for high and low AURKA-CN tumours by KRAS mutational status and the use of cetuximab	KRAS	tumours	
263	Interestingly, among patients with KRAS wild-type tumours, high AURKA-CN appeared to have the largest association with outcome among patients who did not receive cetuximab	AURKA	KRAS wild-type tumours	
264	A significantly longer OS was noted among patients with high vs low AURKA-CN (median OS 48.6 months for patients with high AURKA-CN tumours compared with 18.8 months for patients with low AURKA-CN tumours, HR=0.28, 95% CI: 0.10-0.73, P=0.01; Figure 4A)	AURKA	tumours	
265	A significantly longer OS was noted among patients with high vs low AURKA-CN (median OS 48.6 months for patients with high AURKA-CN tumours compared with 18.8 months for patients with low AURKA-CN tumours, HR=0.28, 95% CI: 0.10-0.73, P=0.01; Figure 4A)	AURKA	low AURKA-CN tumours	
266	A significantly longer OS was noted among patients with high vs low AURKA-CN (median OS 48.6 months for patients with high AURKA-CN tumours compared with 18.8 months for patients with low AURKA-CN tumours, HR=0.28, 95% CI: 0.10-0.73, P=0.01; Figure 4A)	AURKA	tumours	
267	A significantly longer OS was noted among patients with high vs low AURKA-CN (median OS 48.6 months for patients with high AURKA-CN tumours compared with 18.8 months for patients with low AURKA-CN tumours, HR=0.28, 95% CI: 0.10-0.73, P=0.01; Figure 4A)	AURKA	low AURKA-CN tumours	
268	In all, 1-year and 2-year survival were also longer among patients with high AURKA-CN tumours compared with those with low AURKA-CN tumours (1 year: 92.5% vs 82.2% P<0.001; 2 year: 80.9% vs 29.9%, P<0.001).	AURKA	tumours	
269	In all, 1-year and 2-year survival were also longer among patients with high AURKA-CN tumours compared with those with low AURKA-CN tumours (1 year: 92.5% vs 82.2% P<0.001; 2 year: 80.9% vs 29.9%, P<0.001).	AURKA	AURKA-CN tumours	
270	Similarly to PFS, the longer OS for patients with high AURKA-CN tumours was particularly pronounced in the KRAS wild-type patient population (Figure 4B)	AURKA	tumours	
271	Similarly to PFS, the longer OS for patients with high AURKA-CN tumours was particularly pronounced in the KRAS wild-type patient population (Figure 4B)	KRAS	tumours	
272	Among patients with KRAS wild-type tumours, the median OS was not reached for high AURKA-CN compared with 18.8 months for the group with low AURKA-CN tumours (HR=0.14, 95% CI: 0.038-0.514, P=0.003)	AURKA	KRAS wild-type tumours	
273	Among patients with KRAS wild-type tumours, the median OS was not reached for high AURKA-CN compared with 18.8 months for the group with low AURKA-CN tumours (HR=0.14, 95% CI: 0.038-0.514, P=0.003)	AURKA	low AURKA-CN tumours	
274	Similarly, increased 1-year and 2-year survival was seen among those patients with KRAS wild-type tumours and high AURKA-CN compared with patients with KRAS wild-type tumours and low AURKA-CN (1 year: 96% vs 75% P<0.0001; 2 year: 93% vs 28% P<0.0001)	KRAS	tumours	
275	Similarly, increased 1-year and 2-year survival was seen among those patients with KRAS wild-type tumours and high AURKA-CN compared with patients with KRAS wild-type tumours and low AURKA-CN (1 year: 96% vs 75% P<0.0001; 2 year: 93% vs 28% P<0.0001)	KRAS	tumours	
276	Similarly, increased 1-year and 2-year survival was seen among those patients with KRAS wild-type tumours and high AURKA-CN compared with patients with KRAS wild-type tumours and low AURKA-CN (1 year: 96% vs 75% P<0.0001; 2 year: 93% vs 28% P<0.0001)	AURKA	tumours	
277	Similarly, increased 1-year and 2-year survival was seen among those patients with KRAS wild-type tumours and high AURKA-CN compared with patients with KRAS wild-type tumours and low AURKA-CN (1 year: 96% vs 75% P<0.0001; 2 year: 93% vs 28% P<0.0001)	KRAS	tumours	
278	Similarly, increased 1-year and 2-year survival was seen among those patients with KRAS wild-type tumours and high AURKA-CN compared with patients with KRAS wild-type tumours and low AURKA-CN (1 year: 96% vs 75% P<0.0001; 2 year: 93% vs 28% P<0.0001)	AURKA	tumours	
279	Similarly, increased 1-year and 2-year survival was seen among those patients with KRAS wild-type tumours and high AURKA-CN compared with patients with KRAS wild-type tumours and low AURKA-CN (1 year: 96% vs 75% P<0.0001; 2 year: 93% vs 28% P<0.0001)	AURKA	tumours	
280	Similarly, increased 1-year and 2-year survival was seen among those patients with KRAS wild-type tumours and high AURKA-CN compared with patients with KRAS wild-type tumours and low AURKA-CN (1 year: 96% vs 75% P<0.0001; 2 year: 93% vs 28% P<0.0001)	KRAS	tumours	
281	Similarly, increased 1-year and 2-year survival was seen among those patients with KRAS wild-type tumours and high AURKA-CN compared with patients with KRAS wild-type tumours and low AURKA-CN (1 year: 96% vs 75% P<0.0001; 2 year: 93% vs 28% P<0.0001)	AURKA	tumours	
282	IHC evaluation of AURKA hyperactivity	AURKA	hyperactivity	
283	Immunohistochemical evaluation of phosphorylated AURKA protein was performed on 27 available tumour samples (20 with high AURKA-CN and 7 with low AURKA-CN)	AURKA	tumour	
284	Immunohistochemical evaluation of phosphorylated AURKA protein was performed on 27 available tumour samples (20 with high AURKA-CN and 7 with low AURKA-CN)	AURKA	tumour	
285	Immunohistochemical evaluation of phosphorylated AURKA protein was performed on 27 available tumour samples (20 with high AURKA-CN and 7 with low AURKA-CN)	AURKA	tumour	
286	Among the seven tumours with low AURKA-CN, none were positive for phosphorylated T-288	AURKA	tumours	
287	However, among the 20 tumours with high AURKA-CN, 9 were found to have positive staining (P=0.06 for difference between high and low AURKA-CN tumours)	AURKA	tumours	
288	However, among the 20 tumours with high AURKA-CN, 9 were found to have positive staining (P=0.06 for difference between high and low AURKA-CN tumours)	AURKA	AURKA-CN tumours	
289	The groups led by and reported increased AURKA-CN in ~30% of CRC tumours	AURKA	CRC tumours	
290	The role of Aurora kinase in tumourigenesis is well documented, although its utility as a prognostic marker is still under investigation in many cancers	Aurora kinase	cancers	
291	reported a high expression of Aurora A by AQUA to be a poor prognostic marker in patients with breast cancer	Aurora A	breast cancer	
292	Similarly overexpression of Aurora kinase B was found to be a poor prognostic marker in non-small cell lung cancer	Aurora kinase B	non-small cell lung cancer	
293	Similarly to our findings, Lam and colleagues have demonstrated higher detection of the AURKA protein by IHC in low-grade (well or moderately differentiated) CRC samples compared with high-grade (poorly differentiated) tumours	AURKA	tumours	
294	Our data demonstrating increased PFS for patients with high AURKA-CN tumours support this hypothesis	AURKA	tumours	
295	The improved OS for patients with high AURKA-CN was most pronounced in our study among patients with KRAS wild-type tumours	AURKA	KRAS wild-type tumours	
296	The improved response of patients with KRAS wild-type tumours treated with anti-EGFR therapy has been well documented in the literature	KRAS	tumours	
297	The improved response of patients with KRAS wild-type tumours treated with anti-EGFR therapy has been well documented in the literature	EGFR	tumours	
298	However in our study, among patients with KRAS wild-type tumours, the impact of high AURKA-CN level was most pronounced in patients who did not receive cetuximab	AURKA	KRAS wild-type tumours	
299	Many groups have studied AURKA protein expression by IHC in CRC and other cancers	AURKA	cancers	
300	Moreover, our study is the first to demonstrate an association between high AURKA-CN and improved clinical outcome among patients with mCRC receiving chemotherapy, with a more pronounced association noted among patients with KRAS wild-type tumours	AURKA	KRAS wild-type tumours	
301	Aurora-A expression is independently associated with chromosomal instability in colorectal cancer	Aurora-A	colorectal cancer	
302	Drosophila Aurora-A is required for centrosome maturation and actin-dependent asymmetric protein localization during mitosis	Aurora-A	mitosis	
303	A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers	aurora kinase	colorectal cancers	
304	K-ras mutations and benefit from cetuximab in advanced colorectal cancer	K-ras	colorectal cancer	
305	Aurora kinase expression in colorectal adenocarcinoma: correlations with clinicopathological features, p16 expression, and telomerase activity	Aurora kinase	colorectal adenocarcinoma	
306	Aurora kinase expression in colorectal adenocarcinoma: correlations with clinicopathological features, p16 expression, and telomerase activity	p16	colorectal adenocarcinoma	
307	Expression of Aurora A (but not Aurora B) is predictive of survival in breast cancer	Aurora A	breast cancer	
308	Expression of Aurora A (but not Aurora B) is predictive of survival in breast cancer	Aurora B	breast cancer	
309	High copy amplification of the Aurora-A gene is associated with chromosomal instability phenotype in human colorectal cancers	Aurora-A	colorectal cancers	
310	Quantitation of Aurora kinase A gene copy number in urine sediments and bladder cancer detection	Aurora kinase A	bladder cancer	
311	Effects of DNAzymes targeting Aurora kinase A on the growth of human prostate cancer	Aurora kinase A	prostate cancer	
312	Overexpression of aurora B kinase (AURKB) in primary non-small cell lung carcinoma is frequent, generally driven from one allele, and correlates with the level of genetic instability	aurora B	carcinoma	
313	Overexpression of aurora B kinase (AURKB) in primary non-small cell lung carcinoma is frequent, generally driven from one allele, and correlates with the level of genetic instability	AURKB	carcinoma	
314	Aurora kinase B is a predictive factor for the aggressive recurrence of hepatocellular carcinoma after curative hepatectomy	Aurora kinase B	hepatocellular carcinoma	
315	Inhibition of Aurora-A suppresses epithelial-mesenchymal transition and invasion by downregulating MAPK in nasopharyngeal carcinoma cells	Aurora-A	carcinoma	
316	Aurora B expression correlates with aggressive behaviour in glioblastoma multiforme	Aurora B	glioblastoma multiforme	
317	Copy number increase of aurora kinase A in colorectal cancers: a correlation with tumor progression	aurora kinase A	colorectal cancers	
318	Copy number increase of aurora kinase A in colorectal cancers: a correlation with tumor progression	aurora kinase A	tumor	
319	Progression-free survival (PFS) of metastatic colorectal cancer patients receiving first-line and second-line chemotherapy by AURKA-CN and KRAS mutation status	AURKA	colorectal cancer	
320	Progression-free survival (PFS) of metastatic colorectal cancer patients receiving first-line and second-line chemotherapy by AURKA-CN and KRAS mutation status	KRAS	colorectal cancer	
321	Overall survival of metastatic colorectal cancer patients by AURKA-CN for entire cohort (A), the KRAS wild-type population (B) and the KRAS mutant population (C).	AURKA	colorectal cancer	
322	Overall survival of metastatic colorectal cancer patients by AURKA-CN for entire cohort (A), the KRAS wild-type population (B) and the KRAS mutant population (C).	KRAS	colorectal cancer	
323	Overall survival of metastatic colorectal cancer patients by AURKA-CN for entire cohort (A), the KRAS wild-type population (B) and the KRAS mutant population (C).	KRAS	colorectal cancer	
324	Immunohistochemistry staining for phosphorylated AURKA in metastatic colorectal cancer samples	AURKA	colorectal cancer	
325	Interplay between BRCA1 and RHAMM Regulates Epithelial Apicobasal Polarization and May Influence Risk of Breast Cancer	BRCA1	Breast Cancer	
326	Interplay between BRCA1 and RHAMM Regulates Epithelial Apicobasal Polarization and May Influence Risk of Breast Cancer	RHAMM	Breast Cancer	
327	Genetic analysis identifies the HMMR gene as a modifier of the breast cancer risk associated with BRCA1 gene mutation, while cell biological analysis of the protein product suggests a function in regulating development of the mammary gland.	HMMR	breast cancer	
328	Genetic analysis identifies the HMMR gene as a modifier of the breast cancer risk associated with BRCA1 gene mutation, while cell biological analysis of the protein product suggests a function in regulating development of the mammary gland.	BRCA1	breast cancer	
329	In BRCA1 mutation carriers, accumulation of stem and progenitor cells in normal breast tissue and increased risk of developing tumors of basal-like type suggest that BRCA1 regulates stem/progenitor cell proliferation and differentiation	BRCA1	tumors	
330	In BRCA1 mutation carriers, accumulation of stem and progenitor cells in normal breast tissue and increased risk of developing tumors of basal-like type suggest that BRCA1 regulates stem/progenitor cell proliferation and differentiation	BRCA1	tumors	
331	However, the function of BRCA1 in this process and its link to carcinogenesis remain unknown	BRCA1	carcinogenesis	
332	Here we depict a molecular mechanism involving BRCA1 and RHAMM that regulates apicobasal polarity and, when perturbed, may increase risk of breast cancer	BRCA1	breast cancer	
333	Here we depict a molecular mechanism involving BRCA1 and RHAMM that regulates apicobasal polarity and, when perturbed, may increase risk of breast cancer	RHAMM	breast cancer	
334	Starting from complementary genetic analyses across families and populations, we identified common genetic variation at the low-penetrance susceptibility HMMR locus (encoding for RHAMM) that modifies breast cancer risk among BRCA1, but probably not BRCA2, mutation carriers: n = 7,584, weighted hazard ratio (wHR) = 1.09 (95% CI 1.02-1.16), ptrend = 0.017; and n = 3,965, wHR = 1.04 (95% CI 0.94-1.16), ptrend = 0.43; respectively	HMMR	breast cancer	
335	Starting from complementary genetic analyses across families and populations, we identified common genetic variation at the low-penetrance susceptibility HMMR locus (encoding for RHAMM) that modifies breast cancer risk among BRCA1, but probably not BRCA2, mutation carriers: n = 7,584, weighted hazard ratio (wHR) = 1.09 (95% CI 1.02-1.16), ptrend = 0.017; and n = 3,965, wHR = 1.04 (95% CI 0.94-1.16), ptrend = 0.43; respectively	RHAMM	breast cancer	
336	Starting from complementary genetic analyses across families and populations, we identified common genetic variation at the low-penetrance susceptibility HMMR locus (encoding for RHAMM) that modifies breast cancer risk among BRCA1, but probably not BRCA2, mutation carriers: n = 7,584, weighted hazard ratio (wHR) = 1.09 (95% CI 1.02-1.16), ptrend = 0.017; and n = 3,965, wHR = 1.04 (95% CI 0.94-1.16), ptrend = 0.43; respectively	BRCA1	breast cancer	
337	Starting from complementary genetic analyses across families and populations, we identified common genetic variation at the low-penetrance susceptibility HMMR locus (encoding for RHAMM) that modifies breast cancer risk among BRCA1, but probably not BRCA2, mutation carriers: n = 7,584, weighted hazard ratio (wHR) = 1.09 (95% CI 1.02-1.16), ptrend = 0.017; and n = 3,965, wHR = 1.04 (95% CI 0.94-1.16), ptrend = 0.43; respectively	BRCA2	breast cancer	
338	Taken together, our data provide fundamental insight into apicobasal polarization through BRCA1 function, which may explain the expanded cell subsets and characteristic tumor type accompanying BRCA1 mutation, while also linking this process to sporadic breast cancer through perturbation of HMMR/RHAMM.	BRCA1	tumor	
339	Taken together, our data provide fundamental insight into apicobasal polarization through BRCA1 function, which may explain the expanded cell subsets and characteristic tumor type accompanying BRCA1 mutation, while also linking this process to sporadic breast cancer through perturbation of HMMR/RHAMM.	BRCA1	breast cancer	
340	Taken together, our data provide fundamental insight into apicobasal polarization through BRCA1 function, which may explain the expanded cell subsets and characteristic tumor type accompanying BRCA1 mutation, while also linking this process to sporadic breast cancer through perturbation of HMMR/RHAMM.	BRCA1	tumor	
341	Taken together, our data provide fundamental insight into apicobasal polarization through BRCA1 function, which may explain the expanded cell subsets and characteristic tumor type accompanying BRCA1 mutation, while also linking this process to sporadic breast cancer through perturbation of HMMR/RHAMM.	HMMR	tumor	
342	Taken together, our data provide fundamental insight into apicobasal polarization through BRCA1 function, which may explain the expanded cell subsets and characteristic tumor type accompanying BRCA1 mutation, while also linking this process to sporadic breast cancer through perturbation of HMMR/RHAMM.	RHAMM	tumor	
343	Taken together, our data provide fundamental insight into apicobasal polarization through BRCA1 function, which may explain the expanded cell subsets and characteristic tumor type accompanying BRCA1 mutation, while also linking this process to sporadic breast cancer through perturbation of HMMR/RHAMM.	BRCA1	breast cancer	
344	Taken together, our data provide fundamental insight into apicobasal polarization through BRCA1 function, which may explain the expanded cell subsets and characteristic tumor type accompanying BRCA1 mutation, while also linking this process to sporadic breast cancer through perturbation of HMMR/RHAMM.	HMMR	breast cancer	
345	Taken together, our data provide fundamental insight into apicobasal polarization through BRCA1 function, which may explain the expanded cell subsets and characteristic tumor type accompanying BRCA1 mutation, while also linking this process to sporadic breast cancer through perturbation of HMMR/RHAMM.	RHAMM	breast cancer	
346	Mutations in two genes that were initially identified as predisposing carriers to early-onset breast cancer, BRCA1 and BRCA2, cause similar perturbations in cellular responses to DNA damage but predispose carriers to distinct tumor types	BRCA1	breast cancer	
347	Mutations in two genes that were initially identified as predisposing carriers to early-onset breast cancer, BRCA1 and BRCA2, cause similar perturbations in cellular responses to DNA damage but predispose carriers to distinct tumor types	BRCA2	breast cancer	
348	Mutations in two genes that were initially identified as predisposing carriers to early-onset breast cancer, BRCA1 and BRCA2, cause similar perturbations in cellular responses to DNA damage but predispose carriers to distinct tumor types	BRCA1	tumor	
349	Mutations in two genes that were initially identified as predisposing carriers to early-onset breast cancer, BRCA1 and BRCA2, cause similar perturbations in cellular responses to DNA damage but predispose carriers to distinct tumor types	BRCA2	tumor	
350	We have used genetic analyses of affected families to uncover additional genetic variation that is linked to the risk of developing cancer for carriers of BRCA1 mutations	BRCA1	cancer	
351	Our findings provide new insights into the mechanism through which BRCA1 may promote commitment of initially bipotent mammary cells towards the luminal lineage, and how loss of this function may predispose cells to become breast tumors of a basal-like type.	BRCA1	breast tumors	
352	The common pathological features of breast tumors arising in breast cancer 1, early onset (BRCA1) gene mutation carriers, including the basal-like phenotype and ER negativity, led to the proposition that BRCA1 function regulates stem/progenitor cell proliferation and differentiation	BRCA1	breast tumors	
353	The common pathological features of breast tumors arising in breast cancer 1, early onset (BRCA1) gene mutation carriers, including the basal-like phenotype and ER negativity, led to the proposition that BRCA1 function regulates stem/progenitor cell proliferation and differentiation	BRCA1	breast tumors	
354	The common pathological features of breast tumors arising in breast cancer 1, early onset (BRCA1) gene mutation carriers, including the basal-like phenotype and ER negativity, led to the proposition that BRCA1 function regulates stem/progenitor cell proliferation and differentiation	BRCA1	breast cancer	
355	The common pathological features of breast tumors arising in breast cancer 1, early onset (BRCA1) gene mutation carriers, including the basal-like phenotype and ER negativity, led to the proposition that BRCA1 function regulates stem/progenitor cell proliferation and differentiation	BRCA1	breast cancer	
356	Expanded luminal progenitor populations have also been detected in breast tissue from BRCA1 mutation carriers and, subsequently, proposed as the target of transformation leading to basal-like tumors	BRCA1	tumors	
357	Xrhamm is the ortholog of a candidate low-penetrance breast cancer susceptibility gene product (RHAMM, HMMR gene) whose over-expression in tumors is associated with poor prognosis and early age at diagnosis	Xrhamm	breast cancer	
358	Xrhamm is the ortholog of a candidate low-penetrance breast cancer susceptibility gene product (RHAMM, HMMR gene) whose over-expression in tumors is associated with poor prognosis and early age at diagnosis	Xrhamm	tumors	
359	Xrhamm is the ortholog of a candidate low-penetrance breast cancer susceptibility gene product (RHAMM, HMMR gene) whose over-expression in tumors is associated with poor prognosis and early age at diagnosis	RHAMM	breast cancer	
360	Xrhamm is the ortholog of a candidate low-penetrance breast cancer susceptibility gene product (RHAMM, HMMR gene) whose over-expression in tumors is associated with poor prognosis and early age at diagnosis	HMMR	breast cancer	
361	Xrhamm is the ortholog of a candidate low-penetrance breast cancer susceptibility gene product (RHAMM, HMMR gene) whose over-expression in tumors is associated with poor prognosis and early age at diagnosis	RHAMM	tumors	
362	Xrhamm is the ortholog of a candidate low-penetrance breast cancer susceptibility gene product (RHAMM, HMMR gene) whose over-expression in tumors is associated with poor prognosis and early age at diagnosis	HMMR	tumors	
363	Conversely, loss of BRCA1 function might impair structural cues of terminal differentiation and, consequently, increase risk of breast cancer characterized by the basal-like tumor type	BRCA1	breast cancer	
364	Conversely, loss of BRCA1 function might impair structural cues of terminal differentiation and, consequently, increase risk of breast cancer characterized by the basal-like tumor type	BRCA1	tumor	
365	Common Genetic Variation in HMMR Modifies Breast Cancer Risk among BRCA1 Mutation Carriers	BRCA1	HMMR Modifies Breast Cancer	
366	Although BRCA1 and BRCA2 function coordinately during DNA damage response, genomic, transcriptomic, molecular, and pathological features of breast tumors arising in BRCA1 and BRCA2 mutation carriers suggest that carcinogenesis may occur through perturbation of shared and distinct biological processes	BRCA1	breast tumors	
367	Although BRCA1 and BRCA2 function coordinately during DNA damage response, genomic, transcriptomic, molecular, and pathological features of breast tumors arising in BRCA1 and BRCA2 mutation carriers suggest that carcinogenesis may occur through perturbation of shared and distinct biological processes	BRCA1	carcinogenesis	
368	Although BRCA1 and BRCA2 function coordinately during DNA damage response, genomic, transcriptomic, molecular, and pathological features of breast tumors arising in BRCA1 and BRCA2 mutation carriers suggest that carcinogenesis may occur through perturbation of shared and distinct biological processes	BRCA2	breast tumors	
369	Although BRCA1 and BRCA2 function coordinately during DNA damage response, genomic, transcriptomic, molecular, and pathological features of breast tumors arising in BRCA1 and BRCA2 mutation carriers suggest that carcinogenesis may occur through perturbation of shared and distinct biological processes	BRCA2	carcinogenesis	
370	Although BRCA1 and BRCA2 function coordinately during DNA damage response, genomic, transcriptomic, molecular, and pathological features of breast tumors arising in BRCA1 and BRCA2 mutation carriers suggest that carcinogenesis may occur through perturbation of shared and distinct biological processes	BRCA1	breast tumors	
371	Although BRCA1 and BRCA2 function coordinately during DNA damage response, genomic, transcriptomic, molecular, and pathological features of breast tumors arising in BRCA1 and BRCA2 mutation carriers suggest that carcinogenesis may occur through perturbation of shared and distinct biological processes	BRCA2	breast tumors	
372	Although BRCA1 and BRCA2 function coordinately during DNA damage response, genomic, transcriptomic, molecular, and pathological features of breast tumors arising in BRCA1 and BRCA2 mutation carriers suggest that carcinogenesis may occur through perturbation of shared and distinct biological processes	BRCA1	carcinogenesis	
373	Although BRCA1 and BRCA2 function coordinately during DNA damage response, genomic, transcriptomic, molecular, and pathological features of breast tumors arising in BRCA1 and BRCA2 mutation carriers suggest that carcinogenesis may occur through perturbation of shared and distinct biological processes	BRCA2	carcinogenesis	
374	Previous analysis of candidate genomic regions using a linkage approach suggested specific modification of breast cancer risk among BRCA1 mutation carriers by common genetic variation at chromosome 5q33-34	BRCA1	breast cancer	
375	Common breast cancer-predisposition alleles may differentially modify breast cancer risk among BRCA1 and BRCA2 mutation carriers	BRCA1	breast cancer	
376	Common breast cancer-predisposition alleles may differentially modify breast cancer risk among BRCA1 and BRCA2 mutation carriers	BRCA2	breast cancer	
377	Common breast cancer-predisposition alleles may differentially modify breast cancer risk among BRCA1 and BRCA2 mutation carriers	BRCA1	breast cancer	
378	Common breast cancer-predisposition alleles may differentially modify breast cancer risk among BRCA1 and BRCA2 mutation carriers	BRCA2	breast cancer	
379	To complement the linkage approach, we evaluated the effect of common HMMR genetic variation on breast cancer risk in BRCA1 and BRCA2 mutation carriers	HMMR	breast cancer	
380	To complement the linkage approach, we evaluated the effect of common HMMR genetic variation on breast cancer risk in BRCA1 and BRCA2 mutation carriers	BRCA1	breast cancer	
381	To complement the linkage approach, we evaluated the effect of common HMMR genetic variation on breast cancer risk in BRCA1 and BRCA2 mutation carriers	BRCA2	breast cancer	
382	Following a pilot study in Italy and Spain, analysis of carriers (n = 11,609) collected through 24 study groups participating in the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) detected significant modification of breast cancer risk by HMMR rs299290 variant among BRCA1, but not BRCA2, mutation carriers: BRCA1 mutation carriers n = 7,584, Cox proportional-hazards regression model, hazard ratio (HR) = 1.08 (95% confidence interval (CI) 1.02-1.13), ptrend = 0.004 (p 2df = 0.014), in the same direction as originally detected in Ashkenazi Jewish populations; BRCA2 mutation carriers n = 3,965, HR = 1.03 (95% CI 0.96-1.10), ptrend = 0.42 (p 2df = 0.67)	BRCA1/2	breast cancer	
383	Following a pilot study in Italy and Spain, analysis of carriers (n = 11,609) collected through 24 study groups participating in the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) detected significant modification of breast cancer risk by HMMR rs299290 variant among BRCA1, but not BRCA2, mutation carriers: BRCA1 mutation carriers n = 7,584, Cox proportional-hazards regression model, hazard ratio (HR) = 1.08 (95% confidence interval (CI) 1.02-1.13), ptrend = 0.004 (p 2df = 0.014), in the same direction as originally detected in Ashkenazi Jewish populations; BRCA2 mutation carriers n = 3,965, HR = 1.03 (95% CI 0.96-1.10), ptrend = 0.42 (p 2df = 0.67)	HMMR	breast cancer	
384	Following a pilot study in Italy and Spain, analysis of carriers (n = 11,609) collected through 24 study groups participating in the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) detected significant modification of breast cancer risk by HMMR rs299290 variant among BRCA1, but not BRCA2, mutation carriers: BRCA1 mutation carriers n = 7,584, Cox proportional-hazards regression model, hazard ratio (HR) = 1.08 (95% confidence interval (CI) 1.02-1.13), ptrend = 0.004 (p 2df = 0.014), in the same direction as originally detected in Ashkenazi Jewish populations; BRCA2 mutation carriers n = 3,965, HR = 1.03 (95% CI 0.96-1.10), ptrend = 0.42 (p 2df = 0.67)	BRCA1	breast cancer	
385	Following a pilot study in Italy and Spain, analysis of carriers (n = 11,609) collected through 24 study groups participating in the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) detected significant modification of breast cancer risk by HMMR rs299290 variant among BRCA1, but not BRCA2, mutation carriers: BRCA1 mutation carriers n = 7,584, Cox proportional-hazards regression model, hazard ratio (HR) = 1.08 (95% confidence interval (CI) 1.02-1.13), ptrend = 0.004 (p 2df = 0.014), in the same direction as originally detected in Ashkenazi Jewish populations; BRCA2 mutation carriers n = 3,965, HR = 1.03 (95% CI 0.96-1.10), ptrend = 0.42 (p 2df = 0.67)	BRCA2	breast cancer	
386	Following a pilot study in Italy and Spain, analysis of carriers (n = 11,609) collected through 24 study groups participating in the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) detected significant modification of breast cancer risk by HMMR rs299290 variant among BRCA1, but not BRCA2, mutation carriers: BRCA1 mutation carriers n = 7,584, Cox proportional-hazards regression model, hazard ratio (HR) = 1.08 (95% confidence interval (CI) 1.02-1.13), ptrend = 0.004 (p 2df = 0.014), in the same direction as originally detected in Ashkenazi Jewish populations; BRCA2 mutation carriers n = 3,965, HR = 1.03 (95% CI 0.96-1.10), ptrend = 0.42 (p 2df = 0.67)	BRCA1	breast cancer	
387	Following a pilot study in Italy and Spain, analysis of carriers (n = 11,609) collected through 24 study groups participating in the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) detected significant modification of breast cancer risk by HMMR rs299290 variant among BRCA1, but not BRCA2, mutation carriers: BRCA1 mutation carriers n = 7,584, Cox proportional-hazards regression model, hazard ratio (HR) = 1.08 (95% confidence interval (CI) 1.02-1.13), ptrend = 0.004 (p 2df = 0.014), in the same direction as originally detected in Ashkenazi Jewish populations; BRCA2 mutation carriers n = 3,965, HR = 1.03 (95% CI 0.96-1.10), ptrend = 0.42 (p 2df = 0.67)	Cox	breast cancer	
388	Following a pilot study in Italy and Spain, analysis of carriers (n = 11,609) collected through 24 study groups participating in the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) detected significant modification of breast cancer risk by HMMR rs299290 variant among BRCA1, but not BRCA2, mutation carriers: BRCA1 mutation carriers n = 7,584, Cox proportional-hazards regression model, hazard ratio (HR) = 1.08 (95% confidence interval (CI) 1.02-1.13), ptrend = 0.004 (p 2df = 0.014), in the same direction as originally detected in Ashkenazi Jewish populations; BRCA2 mutation carriers n = 3,965, HR = 1.03 (95% CI 0.96-1.10), ptrend = 0.42 (p 2df = 0.67)	BRCA2	breast cancer	
389	Effect of HMMR rs299290 variation on breast cancer risk among BRCA1 and BRCA2 mutation carriers.	HMMR	breast cancer	
390	Effect of HMMR rs299290 variation on breast cancer risk among BRCA1 and BRCA2 mutation carriers.	BRCA1	breast cancer	
391	Effect of HMMR rs299290 variation on breast cancer risk among BRCA1 and BRCA2 mutation carriers.	BRCA2	breast cancer	
392	First, since prophylactic oophorectomy reduces the risk of breast cancer in BRCA1 mutation carriers by up to 50%, we included this observation as a time-dependent covariate in the analysis, and a significant association similar to the one shown above was revealed: HR = 1.09 (95% CI 1.03-1.16), ptrend = 4.5x10-4	BRCA1	breast cancer	
393	While studies have identified low-penetrance alleles that associate with breast cancer risk in carriers of BRCA1 mutations and carriers of BRCA2 mutations, specificities have also been detected	BRCA1	breast cancer	
394	While studies have identified low-penetrance alleles that associate with breast cancer risk in carriers of BRCA1 mutations and carriers of BRCA2 mutations, specificities have also been detected	BRCA2	breast cancer	
395	Here, the results of linkage and association studies support a potential, specific genetic interaction between BRCA1 and HMMR (high- and low-penetrance mutations, respectively), which could highlight a BRCA1-RHAMM function altered in familial and sporadic breast carcinogenesis.	BRCA1	breast carcinogenesis	
396	Here, the results of linkage and association studies support a potential, specific genetic interaction between BRCA1 and HMMR (high- and low-penetrance mutations, respectively), which could highlight a BRCA1-RHAMM function altered in familial and sporadic breast carcinogenesis.	HMMR	breast carcinogenesis	
397	Here, the results of linkage and association studies support a potential, specific genetic interaction between BRCA1 and HMMR (high- and low-penetrance mutations, respectively), which could highlight a BRCA1-RHAMM function altered in familial and sporadic breast carcinogenesis.	BRCA1	breast carcinogenesis	
398	Here, the results of linkage and association studies support a potential, specific genetic interaction between BRCA1 and HMMR (high- and low-penetrance mutations, respectively), which could highlight a BRCA1-RHAMM function altered in familial and sporadic breast carcinogenesis.	RHAMM	breast carcinogenesis	
399	Breast tumors arising in BRCA1 mutation carriers are typically ER-negative, whereas most tumors in BRCA2 mutation carriers and sporadic cases are ER-positive	BRCA1	Breast tumors	
400	Breast tumors arising in BRCA1 mutation carriers are typically ER-negative, whereas most tumors in BRCA2 mutation carriers and sporadic cases are ER-positive	ER	Breast tumors	
401	Breast tumors arising in BRCA1 mutation carriers are typically ER-negative, whereas most tumors in BRCA2 mutation carriers and sporadic cases are ER-positive	BRCA2	Breast tumors	
402	Breast tumors arising in BRCA1 mutation carriers are typically ER-negative, whereas most tumors in BRCA2 mutation carriers and sporadic cases are ER-positive	ER	Breast tumors	
403	Breast tumors arising in BRCA1 mutation carriers are typically ER-negative, whereas most tumors in BRCA2 mutation carriers and sporadic cases are ER-positive	BRCA1	tumors	
404	Breast tumors arising in BRCA1 mutation carriers are typically ER-negative, whereas most tumors in BRCA2 mutation carriers and sporadic cases are ER-positive	ER	tumors	
405	Breast tumors arising in BRCA1 mutation carriers are typically ER-negative, whereas most tumors in BRCA2 mutation carriers and sporadic cases are ER-positive	BRCA2	tumors	
406	Breast tumors arising in BRCA1 mutation carriers are typically ER-negative, whereas most tumors in BRCA2 mutation carriers and sporadic cases are ER-positive	ER	tumors	
407	Given the evidence above, we next evaluated whether HMMR variation was associated with ER tumor status in BRCA1 and/or BRCA2 mutation carriers	HMMR	tumor	
408	Given the evidence above, we next evaluated whether HMMR variation was associated with ER tumor status in BRCA1 and/or BRCA2 mutation carriers	ER	tumor	
409	Given the evidence above, we next evaluated whether HMMR variation was associated with ER tumor status in BRCA1 and/or BRCA2 mutation carriers	BRCA1	tumor	
410	Given the evidence above, we next evaluated whether HMMR variation was associated with ER tumor status in BRCA1 and/or BRCA2 mutation carriers	BRCA2	tumor	
411	In data provided by several CIMBA groups (Text S1), no ER-positive tumors were observed among rare rs299290 homozygotes in BRCA1 mutation carriers (p interaction = 0.006), whereas this bias was not observed in BRCA2 mutation carriers (p interaction = 0.95) (Table S4)	ER	tumors	
412	In data provided by several CIMBA groups (Text S1), no ER-positive tumors were observed among rare rs299290 homozygotes in BRCA1 mutation carriers (p interaction = 0.006), whereas this bias was not observed in BRCA2 mutation carriers (p interaction = 0.95) (Table S4)	BRCA1	tumors	
413	In data provided by several CIMBA groups (Text S1), no ER-positive tumors were observed among rare rs299290 homozygotes in BRCA1 mutation carriers (p interaction = 0.006), whereas this bias was not observed in BRCA2 mutation carriers (p interaction = 0.95) (Table S4)	BRCA2	tumors	
414	That is, despite the expected differences in the frequency of tumor types between the two sets of carriers, heterogeneity was observed in the distribution of rs299290 genotypes in BRCA1, but not BRCA2, mutation carriers	BRCA1	tumor	
415	That is, despite the expected differences in the frequency of tumor types between the two sets of carriers, heterogeneity was observed in the distribution of rs299290 genotypes in BRCA1, but not BRCA2, mutation carriers	BRCA2	tumor	
416	The growth of nonmalignant human mammary epithelial cells, such as MCF10A and HMT3522 S1, within three-dimensional cultures containing reconstituted basement membrane (rBM) recapitulates aspects of the terminal differentiation of mammary luminal epithelia, including apicobasal polarization, growth arrest, and milk production	HMT	luminal epithelia	
417	The growth of nonmalignant human mammary epithelial cells, such as MCF10A and HMT3522 S1, within three-dimensional cultures containing reconstituted basement membrane (rBM) recapitulates aspects of the terminal differentiation of mammary luminal epithelia, including apicobasal polarization, growth arrest, and milk production	HMT	growth arrest	
418	Thus, loss of BRCA1 function may impair polarization by altering intracellular cytoskeletal organization, resulting in intermediate filament content consistent with the characteristic basal-like tumor type.	BRCA1	tumor	
419	While BRCA1 haploinsufficiency does not preclude the formation of a functional luminal layer, the cytoskeletal structure within luminal epithelia from BRCA1 mutation carriers might be compromised	BRCA1	BRCA1 haploinsufficiency	
420	While BRCA1 haploinsufficiency does not preclude the formation of a functional luminal layer, the cytoskeletal structure within luminal epithelia from BRCA1 mutation carriers might be compromised	BRCA1	luminal epithelia	
421	Importantly, both proteasome inhibition and BRCA1 depletion increased the abundance of RHAMM (Figure S7), which is also consistent with observed RHAMM over-expression in breast cancer cell lines derived from BRCA1 mutation carriers	BRCA1	breast cancer	
422	Importantly, both proteasome inhibition and BRCA1 depletion increased the abundance of RHAMM (Figure S7), which is also consistent with observed RHAMM over-expression in breast cancer cell lines derived from BRCA1 mutation carriers	RHAMM	breast cancer	
423	Importantly, both proteasome inhibition and BRCA1 depletion increased the abundance of RHAMM (Figure S7), which is also consistent with observed RHAMM over-expression in breast cancer cell lines derived from BRCA1 mutation carriers	RHAMM	breast cancer	
424	Importantly, both proteasome inhibition and BRCA1 depletion increased the abundance of RHAMM (Figure S7), which is also consistent with observed RHAMM over-expression in breast cancer cell lines derived from BRCA1 mutation carriers	BRCA1	breast cancer	
425	Consistent with previous reports, total RHAMM decorates all microtubule structures throughout mitosis	RHAMM	mitosis	
426	Threonine 703 (T703) is an evolutionarily conserved phosphorylated residue in RHAMM similar to a consensus aurora kinase Ipl1p site	RHAMM	consensus aurora	
427	Threonine 703 (T703) is an evolutionarily conserved phosphorylated residue in RHAMM similar to a consensus aurora kinase Ipl1p site	Ipl1p	consensus aurora	
428	pT703-RHAMM Expression in BRCA1 Mutant Breast Cancer Cells and Tumors; A Mechanistic Model for Polarization and Increased Risk of Breast Cancer	RHAMM	Breast Cancer Cells and Tumors	
429	pT703-RHAMM Expression in BRCA1 Mutant Breast Cancer Cells and Tumors; A Mechanistic Model for Polarization and Increased Risk of Breast Cancer	RHAMM	Breast Cancer	
430	pT703-RHAMM Expression in BRCA1 Mutant Breast Cancer Cells and Tumors; A Mechanistic Model for Polarization and Increased Risk of Breast Cancer	BRCA1	Breast Cancer Cells and Tumors	
431	pT703-RHAMM Expression in BRCA1 Mutant Breast Cancer Cells and Tumors; A Mechanistic Model for Polarization and Increased Risk of Breast Cancer	BRCA1	Breast Cancer	
432	To evaluate the link with carcinogenesis, pT703-RHAMM immunochemistry was performed in BRCA1 mutant breast cancer cells, HCC1937 line, their wild-type reconstituted counterparts, and in primary breast tumors	RHAMM	carcinogenesis	
433	To evaluate the link with carcinogenesis, pT703-RHAMM immunochemistry was performed in BRCA1 mutant breast cancer cells, HCC1937 line, their wild-type reconstituted counterparts, and in primary breast tumors	BRCA1	carcinogenesis	
434	To evaluate the link with carcinogenesis, pT703-RHAMM immunochemistry was performed in BRCA1 mutant breast cancer cells, HCC1937 line, their wild-type reconstituted counterparts, and in primary breast tumors	RHAMM	breast cancer	
435	To evaluate the link with carcinogenesis, pT703-RHAMM immunochemistry was performed in BRCA1 mutant breast cancer cells, HCC1937 line, their wild-type reconstituted counterparts, and in primary breast tumors	RHAMM	breast tumors	
436	To evaluate the link with carcinogenesis, pT703-RHAMM immunochemistry was performed in BRCA1 mutant breast cancer cells, HCC1937 line, their wild-type reconstituted counterparts, and in primary breast tumors	BRCA1	breast cancer	
437	To evaluate the link with carcinogenesis, pT703-RHAMM immunochemistry was performed in BRCA1 mutant breast cancer cells, HCC1937 line, their wild-type reconstituted counterparts, and in primary breast tumors	BRCA1	breast tumors	
438	Subsequently, high expression of pT703-RHAMM was scored in 58% (n = 11) and 50% (n = 4) of BRCA1 mutation carriers and sporadic ER-negative tumors, respectively, but in 36% (n = 5) and 30% (n = 10) of BRCA2 mutation carriers and sporadic ER-positive tumors, respectively (Figure 7B)	pT703-RHAMM	tumors	
439	Subsequently, high expression of pT703-RHAMM was scored in 58% (n = 11) and 50% (n = 4) of BRCA1 mutation carriers and sporadic ER-negative tumors, respectively, but in 36% (n = 5) and 30% (n = 10) of BRCA2 mutation carriers and sporadic ER-positive tumors, respectively (Figure 7B)	pT703-RHAMM	tumors	
440	Subsequently, high expression of pT703-RHAMM was scored in 58% (n = 11) and 50% (n = 4) of BRCA1 mutation carriers and sporadic ER-negative tumors, respectively, but in 36% (n = 5) and 30% (n = 10) of BRCA2 mutation carriers and sporadic ER-positive tumors, respectively (Figure 7B)	BRCA1	tumors	
441	Subsequently, high expression of pT703-RHAMM was scored in 58% (n = 11) and 50% (n = 4) of BRCA1 mutation carriers and sporadic ER-negative tumors, respectively, but in 36% (n = 5) and 30% (n = 10) of BRCA2 mutation carriers and sporadic ER-positive tumors, respectively (Figure 7B)	BRCA1	tumors	
442	Subsequently, high expression of pT703-RHAMM was scored in 58% (n = 11) and 50% (n = 4) of BRCA1 mutation carriers and sporadic ER-negative tumors, respectively, but in 36% (n = 5) and 30% (n = 10) of BRCA2 mutation carriers and sporadic ER-positive tumors, respectively (Figure 7B)	ER	tumors	
443	Subsequently, high expression of pT703-RHAMM was scored in 58% (n = 11) and 50% (n = 4) of BRCA1 mutation carriers and sporadic ER-negative tumors, respectively, but in 36% (n = 5) and 30% (n = 10) of BRCA2 mutation carriers and sporadic ER-positive tumors, respectively (Figure 7B)	ER	tumors	
444	Subsequently, high expression of pT703-RHAMM was scored in 58% (n = 11) and 50% (n = 4) of BRCA1 mutation carriers and sporadic ER-negative tumors, respectively, but in 36% (n = 5) and 30% (n = 10) of BRCA2 mutation carriers and sporadic ER-positive tumors, respectively (Figure 7B)	BRCA2	tumors	
445	Subsequently, high expression of pT703-RHAMM was scored in 58% (n = 11) and 50% (n = 4) of BRCA1 mutation carriers and sporadic ER-negative tumors, respectively, but in 36% (n = 5) and 30% (n = 10) of BRCA2 mutation carriers and sporadic ER-positive tumors, respectively (Figure 7B)	ER	tumors	
446	Subsequently, high expression of pT703-RHAMM was scored in 58% (n = 11) and 50% (n = 4) of BRCA1 mutation carriers and sporadic ER-negative tumors, respectively, but in 36% (n = 5) and 30% (n = 10) of BRCA2 mutation carriers and sporadic ER-positive tumors, respectively (Figure 7B)	BRCA2	tumors	
447	Subsequently, high expression of pT703-RHAMM was scored in 58% (n = 11) and 50% (n = 4) of BRCA1 mutation carriers and sporadic ER-negative tumors, respectively, but in 36% (n = 5) and 30% (n = 10) of BRCA2 mutation carriers and sporadic ER-positive tumors, respectively (Figure 7B)	ER	tumors	
448	Although this dataset is limited, the results support the indication of an interplay between BRCA1 and RHAMM, which is altered in breast carcinogenesis.	BRCA1	breast carcinogenesis	
449	Although this dataset is limited, the results support the indication of an interplay between BRCA1 and RHAMM, which is altered in breast carcinogenesis.	RHAMM	breast carcinogenesis	
450	pT703-RHAMM expression in BRCA1 mutant breast cancer cells and tumors.	RHAMM	breast cancer	
451	pT703-RHAMM expression in BRCA1 mutant breast cancer cells and tumors.	RHAMM	tumors	
452	pT703-RHAMM expression in BRCA1 mutant breast cancer cells and tumors.	BRCA1	breast cancer	
453	pT703-RHAMM expression in BRCA1 mutant breast cancer cells and tumors.	BRCA1	tumors	
454	(B) Results of pT703-RHAMM staining scores in primary breast tumors with different BRCA1/2 mutation and ER status	pT703-RHAMM	breast tumors	
455	(B) Results of pT703-RHAMM staining scores in primary breast tumors with different BRCA1/2 mutation and ER status	BRCA1	breast tumors	
456	(B) Results of pT703-RHAMM staining scores in primary breast tumors with different BRCA1/2 mutation and ER status	ER	breast tumors	
457	This model is consistent with reduced expression of AURKA, TPX2, and HMMR, but to a lesser extent BRCA1, with polarization and growth arrest of nonmalignant mammary epithelial cells, as measured by gene expression profiling (Figure S11A)	AURKA	growth arrest	
458	This model is consistent with reduced expression of AURKA, TPX2, and HMMR, but to a lesser extent BRCA1, with polarization and growth arrest of nonmalignant mammary epithelial cells, as measured by gene expression profiling (Figure S11A)	TPX2	growth arrest	
459	This model is consistent with reduced expression of AURKA, TPX2, and HMMR, but to a lesser extent BRCA1, with polarization and growth arrest of nonmalignant mammary epithelial cells, as measured by gene expression profiling (Figure S11A)	HMMR	growth arrest	
460	This model is consistent with reduced expression of AURKA, TPX2, and HMMR, but to a lesser extent BRCA1, with polarization and growth arrest of nonmalignant mammary epithelial cells, as measured by gene expression profiling (Figure S11A)	BRCA1	growth arrest	
461	Deviation from this pathway, through loss of BRCA1 function or augmentation of microtubule-associated factors, may impair terminal differentiation of luminal epithelia and promote tumorigenesis	BRCA1	luminal epithelia	
462	Consistently, HMMR over-expression might be detectable as early as the transition from normal breast tissue to hyperplasia (Figure S11B)	HMMR	hyperplasia	
463	We have investigated gene and protein interactions in a centrosome-cantered module, including BRCA1/BRCA1 and HMMR/RHAMM, across biological systems ranging from breast cancer risk estimates to cellular phenotypes and cytoskeletal structures	BRCA1	breast cancer	
464	We have investigated gene and protein interactions in a centrosome-cantered module, including BRCA1/BRCA1 and HMMR/RHAMM, across biological systems ranging from breast cancer risk estimates to cellular phenotypes and cytoskeletal structures	BRCA1	breast cancer	
465	We have investigated gene and protein interactions in a centrosome-cantered module, including BRCA1/BRCA1 and HMMR/RHAMM, across biological systems ranging from breast cancer risk estimates to cellular phenotypes and cytoskeletal structures	HMMR	breast cancer	
466	We have investigated gene and protein interactions in a centrosome-cantered module, including BRCA1/BRCA1 and HMMR/RHAMM, across biological systems ranging from breast cancer risk estimates to cellular phenotypes and cytoskeletal structures	RHAMM	breast cancer	
467	Accordingly, a common candidate breast cancer-predisposition allele in HMMR, originally identified in an Ashkenazi Jewish study, may specifically modify breast cancer risk among BRCA1 mutation carriers	HMMR	breast cancer	
468	Accordingly, a common candidate breast cancer-predisposition allele in HMMR, originally identified in an Ashkenazi Jewish study, may specifically modify breast cancer risk among BRCA1 mutation carriers	BRCA1	breast cancer	
469	Accordingly, a common candidate breast cancer-predisposition allele in HMMR, originally identified in an Ashkenazi Jewish study, may specifically modify breast cancer risk among BRCA1 mutation carriers	HMMR	breast cancer	
470	Accordingly, a common candidate breast cancer-predisposition allele in HMMR, originally identified in an Ashkenazi Jewish study, may specifically modify breast cancer risk among BRCA1 mutation carriers	BRCA1	breast cancer	
471	A recent report has suggested that common genetic variation in genes encoding for centrosome pathway components (excluding AURKA and HMMR) may frequently influence risk of breast cancer and, notably, includes variants in TACC3-a proposed HMMR homolog -TUBG1, and TPX2 loci	AURKA	breast cancer	
472	A recent report has suggested that common genetic variation in genes encoding for centrosome pathway components (excluding AURKA and HMMR) may frequently influence risk of breast cancer and, notably, includes variants in TACC3-a proposed HMMR homolog -TUBG1, and TPX2 loci	HMMR	breast cancer	
473	A recent report has suggested that common genetic variation in genes encoding for centrosome pathway components (excluding AURKA and HMMR) may frequently influence risk of breast cancer and, notably, includes variants in TACC3-a proposed HMMR homolog -TUBG1, and TPX2 loci	TACC3	breast cancer	
474	A recent report has suggested that common genetic variation in genes encoding for centrosome pathway components (excluding AURKA and HMMR) may frequently influence risk of breast cancer and, notably, includes variants in TACC3-a proposed HMMR homolog -TUBG1, and TPX2 loci	HMMR	breast cancer	
475	A recent report has suggested that common genetic variation in genes encoding for centrosome pathway components (excluding AURKA and HMMR) may frequently influence risk of breast cancer and, notably, includes variants in TACC3-a proposed HMMR homolog -TUBG1, and TPX2 loci	TUBG1	breast cancer	
476	A recent report has suggested that common genetic variation in genes encoding for centrosome pathway components (excluding AURKA and HMMR) may frequently influence risk of breast cancer and, notably, includes variants in TACC3-a proposed HMMR homolog -TUBG1, and TPX2 loci	TPX2	breast cancer	
477	A unifying mechanism of breast carcinogenesis linked to BRCA1 loss-of-function should provide a comprehensive explanation for the observed accumulation of stem and luminal progenitor cells, and for the characteristic pathological features of the corresponding tumors	BRCA1	breast carcinogenesis	
478	A unifying mechanism of breast carcinogenesis linked to BRCA1 loss-of-function should provide a comprehensive explanation for the observed accumulation of stem and luminal progenitor cells, and for the characteristic pathological features of the corresponding tumors	BRCA1	tumors	
479	Should BRCA1 function(s) promote this transition in mammary stem/progenitor cells, impaired luminal differentiation in BRCA1 mutation carriers and a propensity to develop basal-like tumors with elevated proliferative capacity would be expected	BRCA1	tumors	
480	Should BRCA1 function(s) promote this transition in mammary stem/progenitor cells, impaired luminal differentiation in BRCA1 mutation carriers and a propensity to develop basal-like tumors with elevated proliferative capacity would be expected	BRCA1	tumors	
481	Accordingly, BRCA1 depletion increases the clonogenic potential of mammary epithelia, while a BRCA1 S308A mutant alters embryonic stem cell differentiation	BRCA1	epithelia	
482	Accordingly, BRCA1 depletion increases the clonogenic potential of mammary epithelia, while a BRCA1 S308A mutant alters embryonic stem cell differentiation	BRCA1	epithelia	
483	A key question remains regarding the significance of BRCA1 function to stem/progenitor differentiation and BRCA1 haploinsufficiency	BRCA1	BRCA1 haploinsufficiency	
484	Examination of histologically normal breast tissue in BRCA1 mutation carriers revealed cellular foci expressing stem cell markers and lacking cytoskeletal structures characteristic of luminal epithelia	BRCA1	luminal epithelia	
485	Thus, BRCA1 dose or mutation type may distinctly affect the tissue architecture and function, leading to differences in the accumulation of stem or progenitor cells, and the resulting tumor type	BRCA1	tumor	
486	"This work was funded by the Spanish Ministries of Health, and Science ane Innovation (CB07/02/2005; FIS 08/1120, 08/1359, 08/1635, and 09/02483; RTICCC RD06/0020/1060 and RD06/0020/0028; Transversal Action Against Cancer; the Spanish Biomedical Research Centre Networks for Epidemiology and Public Health, and Rare Diseases; and the ""Ramon y Cajal"" Young Investigator Program), the Spanish National Society of Medical Oncology (2010), the Spanish Association Against Cancer (AECC 2010), the AGAUR Catalan Government Agency (2009SGR1489 and 2009SGR293; and the Beatriu Pinos Postdoctoral Program), the Ramon Areces Foundation (XV), the ""Roses Contra el Cancer"" Foundation, the Michael Cuccione Foundation for Childhood Cancer Research, Cancer Research-UK (C490/A10119, C1287/A8874, C1287/A10118, C5047/A8385, and C8197/A10123), the National Institute for Health Research (UK), the Association for International Cancer Research (AICR-07-0454), the Ligue National Contre le Cancer (France), the Association ""Le cancer du sein, parlons-en!"", the Dutch Cancer Society (NKI 1998-1854, 2004-3088, and 2007-3756), the Fondazione Italiana per la Ricerca sul Cancro (""Hereditary Tumors""), the Associazione Italiana per la Ricerca sul Cancro (4017), the Italian Ministero della Salute (RFPS-2006-3-340203 and ""Progetto Tumori Femminili""), the Italian Ministero dell'Universita' e Ricerca (RBLAO3-BETH), the Fondazione IRCCS Istituto Nazionale Tumori (INT ""5x1000""), the Fondazione Cassa di Risparmio di Pisa (Istituto Toscano Tumori), the National Breast Cancer Foundation (Australia), the Australian National Health and Medical Research Council (145684, 288704, and 454508), the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania, and South Australia, the Cancer Foundation of Western Australia, the German Cancer Aid (107054), the Center for Molecular Medicine Cologne (TV93), the National Cancer Institute (USA; CA128978 and CA122340), National Institutes of Health (RFA-CA-06-503, BCFR U01 CA69398, CA69417, CA69446, CA69467, CA69631, and CA69638), the Research Triangle Institute Informatics Support Center (RFP N02PC45022-46), the Specialized Program of Research Excellence (SPORE P50 CA83638 and CA113916), the Department of Defense Breast Cancer Research Program (05/0612), the Eileen Stein Jacoby Fund, the Breast Cancer Research Foundation, the Marianne and Robert MacDonald Foundation, the Komen Foundation, the Helsinki University Central Hospital Research Fund, the Academy of Finland (110663), the Finnish Cancer Society, the Sigrid Juselius Foundation, and the EU FP7 (223175, HEALTH-F2-2009-223175)"	FIS	Contra el Cancer	
487	"This work was funded by the Spanish Ministries of Health, and Science ane Innovation (CB07/02/2005; FIS 08/1120, 08/1359, 08/1635, and 09/02483; RTICCC RD06/0020/1060 and RD06/0020/0028; Transversal Action Against Cancer; the Spanish Biomedical Research Centre Networks for Epidemiology and Public Health, and Rare Diseases; and the ""Ramon y Cajal"" Young Investigator Program), the Spanish National Society of Medical Oncology (2010), the Spanish Association Against Cancer (AECC 2010), the AGAUR Catalan Government Agency (2009SGR1489 and 2009SGR293; and the Beatriu Pinos Postdoctoral Program), the Ramon Areces Foundation (XV), the ""Roses Contra el Cancer"" Foundation, the Michael Cuccione Foundation for Childhood Cancer Research, Cancer Research-UK (C490/A10119, C1287/A8874, C1287/A10118, C5047/A8385, and C8197/A10123), the National Institute for Health Research (UK), the Association for International Cancer Research (AICR-07-0454), the Ligue National Contre le Cancer (France), the Association ""Le cancer du sein, parlons-en!"", the Dutch Cancer Society (NKI 1998-1854, 2004-3088, and 2007-3756), the Fondazione Italiana per la Ricerca sul Cancro (""Hereditary Tumors""), the Associazione Italiana per la Ricerca sul Cancro (4017), the Italian Ministero della Salute (RFPS-2006-3-340203 and ""Progetto Tumori Femminili""), the Italian Ministero dell'Universita' e Ricerca (RBLAO3-BETH), the Fondazione IRCCS Istituto Nazionale Tumori (INT ""5x1000""), the Fondazione Cassa di Risparmio di Pisa (Istituto Toscano Tumori), the National Breast Cancer Foundation (Australia), the Australian National Health and Medical Research Council (145684, 288704, and 454508), the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania, and South Australia, the Cancer Foundation of Western Australia, the German Cancer Aid (107054), the Center for Molecular Medicine Cologne (TV93), the National Cancer Institute (USA; CA128978 and CA122340), National Institutes of Health (RFA-CA-06-503, BCFR U01 CA69398, CA69417, CA69446, CA69467, CA69631, and CA69638), the Research Triangle Institute Informatics Support Center (RFP N02PC45022-46), the Specialized Program of Research Excellence (SPORE P50 CA83638 and CA113916), the Department of Defense Breast Cancer Research Program (05/0612), the Eileen Stein Jacoby Fund, the Breast Cancer Research Foundation, the Marianne and Robert MacDonald Foundation, the Komen Foundation, the Helsinki University Central Hospital Research Fund, the Academy of Finland (110663), the Finnish Cancer Society, the Sigrid Juselius Foundation, and the EU FP7 (223175, HEALTH-F2-2009-223175)"	FIS	Childhood Cancer	
488	"This work was funded by the Spanish Ministries of Health, and Science ane Innovation (CB07/02/2005; FIS 08/1120, 08/1359, 08/1635, and 09/02483; RTICCC RD06/0020/1060 and RD06/0020/0028; Transversal Action Against Cancer; the Spanish Biomedical Research Centre Networks for Epidemiology and Public Health, and Rare Diseases; and the ""Ramon y Cajal"" Young Investigator Program), the Spanish National Society of Medical Oncology (2010), the Spanish Association Against Cancer (AECC 2010), the AGAUR Catalan Government Agency (2009SGR1489 and 2009SGR293; and the Beatriu Pinos Postdoctoral Program), the Ramon Areces Foundation (XV), the ""Roses Contra el Cancer"" Foundation, the Michael Cuccione Foundation for Childhood Cancer Research, Cancer Research-UK (C490/A10119, C1287/A8874, C1287/A10118, C5047/A8385, and C8197/A10123), the National Institute for Health Research (UK), the Association for International Cancer Research (AICR-07-0454), the Ligue National Contre le Cancer (France), the Association ""Le cancer du sein, parlons-en!"", the Dutch Cancer Society (NKI 1998-1854, 2004-3088, and 2007-3756), the Fondazione Italiana per la Ricerca sul Cancro (""Hereditary Tumors""), the Associazione Italiana per la Ricerca sul Cancro (4017), the Italian Ministero della Salute (RFPS-2006-3-340203 and ""Progetto Tumori Femminili""), the Italian Ministero dell'Universita' e Ricerca (RBLAO3-BETH), the Fondazione IRCCS Istituto Nazionale Tumori (INT ""5x1000""), the Fondazione Cassa di Risparmio di Pisa (Istituto Toscano Tumori), the National Breast Cancer Foundation (Australia), the Australian National Health and Medical Research Council (145684, 288704, and 454508), the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania, and South Australia, the Cancer Foundation of Western Australia, the German Cancer Aid (107054), the Center for Molecular Medicine Cologne (TV93), the National Cancer Institute (USA; CA128978 and CA122340), National Institutes of Health (RFA-CA-06-503, BCFR U01 CA69398, CA69417, CA69446, CA69467, CA69631, and CA69638), the Research Triangle Institute Informatics Support Center (RFP N02PC45022-46), the Specialized Program of Research Excellence (SPORE P50 CA83638 and CA113916), the Department of Defense Breast Cancer Research Program (05/0612), the Eileen Stein Jacoby Fund, the Breast Cancer Research Foundation, the Marianne and Robert MacDonald Foundation, the Komen Foundation, the Helsinki University Central Hospital Research Fund, the Academy of Finland (110663), the Finnish Cancer Society, the Sigrid Juselius Foundation, and the EU FP7 (223175, HEALTH-F2-2009-223175)"	FIS	cancer	
489	"This work was funded by the Spanish Ministries of Health, and Science ane Innovation (CB07/02/2005; FIS 08/1120, 08/1359, 08/1635, and 09/02483; RTICCC RD06/0020/1060 and RD06/0020/0028; Transversal Action Against Cancer; the Spanish Biomedical Research Centre Networks for Epidemiology and Public Health, and Rare Diseases; and the ""Ramon y Cajal"" Young Investigator Program), the Spanish National Society of Medical Oncology (2010), the Spanish Association Against Cancer (AECC 2010), the AGAUR Catalan Government Agency (2009SGR1489 and 2009SGR293; and the Beatriu Pinos Postdoctoral Program), the Ramon Areces Foundation (XV), the ""Roses Contra el Cancer"" Foundation, the Michael Cuccione Foundation for Childhood Cancer Research, Cancer Research-UK (C490/A10119, C1287/A8874, C1287/A10118, C5047/A8385, and C8197/A10123), the National Institute for Health Research (UK), the Association for International Cancer Research (AICR-07-0454), the Ligue National Contre le Cancer (France), the Association ""Le cancer du sein, parlons-en!"", the Dutch Cancer Society (NKI 1998-1854, 2004-3088, and 2007-3756), the Fondazione Italiana per la Ricerca sul Cancro (""Hereditary Tumors""), the Associazione Italiana per la Ricerca sul Cancro (4017), the Italian Ministero della Salute (RFPS-2006-3-340203 and ""Progetto Tumori Femminili""), the Italian Ministero dell'Universita' e Ricerca (RBLAO3-BETH), the Fondazione IRCCS Istituto Nazionale Tumori (INT ""5x1000""), the Fondazione Cassa di Risparmio di Pisa (Istituto Toscano Tumori), the National Breast Cancer Foundation (Australia), the Australian National Health and Medical Research Council (145684, 288704, and 454508), the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania, and South Australia, the Cancer Foundation of Western Australia, the German Cancer Aid (107054), the Center for Molecular Medicine Cologne (TV93), the National Cancer Institute (USA; CA128978 and CA122340), National Institutes of Health (RFA-CA-06-503, BCFR U01 CA69398, CA69417, CA69446, CA69467, CA69631, and CA69638), the Research Triangle Institute Informatics Support Center (RFP N02PC45022-46), the Specialized Program of Research Excellence (SPORE P50 CA83638 and CA113916), the Department of Defense Breast Cancer Research Program (05/0612), the Eileen Stein Jacoby Fund, the Breast Cancer Research Foundation, the Marianne and Robert MacDonald Foundation, the Komen Foundation, the Helsinki University Central Hospital Research Fund, the Academy of Finland (110663), the Finnish Cancer Society, the Sigrid Juselius Foundation, and the EU FP7 (223175, HEALTH-F2-2009-223175)"	FIS	Hereditary Tumors	
490	"This work was funded by the Spanish Ministries of Health, and Science ane Innovation (CB07/02/2005; FIS 08/1120, 08/1359, 08/1635, and 09/02483; RTICCC RD06/0020/1060 and RD06/0020/0028; Transversal Action Against Cancer; the Spanish Biomedical Research Centre Networks for Epidemiology and Public Health, and Rare Diseases; and the ""Ramon y Cajal"" Young Investigator Program), the Spanish National Society of Medical Oncology (2010), the Spanish Association Against Cancer (AECC 2010), the AGAUR Catalan Government Agency (2009SGR1489 and 2009SGR293; and the Beatriu Pinos Postdoctoral Program), the Ramon Areces Foundation (XV), the ""Roses Contra el Cancer"" Foundation, the Michael Cuccione Foundation for Childhood Cancer Research, Cancer Research-UK (C490/A10119, C1287/A8874, C1287/A10118, C5047/A8385, and C8197/A10123), the National Institute for Health Research (UK), the Association for International Cancer Research (AICR-07-0454), the Ligue National Contre le Cancer (France), the Association ""Le cancer du sein, parlons-en!"", the Dutch Cancer Society (NKI 1998-1854, 2004-3088, and 2007-3756), the Fondazione Italiana per la Ricerca sul Cancro (""Hereditary Tumors""), the Associazione Italiana per la Ricerca sul Cancro (4017), the Italian Ministero della Salute (RFPS-2006-3-340203 and ""Progetto Tumori Femminili""), the Italian Ministero dell'Universita' e Ricerca (RBLAO3-BETH), the Fondazione IRCCS Istituto Nazionale Tumori (INT ""5x1000""), the Fondazione Cassa di Risparmio di Pisa (Istituto Toscano Tumori), the National Breast Cancer Foundation (Australia), the Australian National Health and Medical Research Council (145684, 288704, and 454508), the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania, and South Australia, the Cancer Foundation of Western Australia, the German Cancer Aid (107054), the Center for Molecular Medicine Cologne (TV93), the National Cancer Institute (USA; CA128978 and CA122340), National Institutes of Health (RFA-CA-06-503, BCFR U01 CA69398, CA69417, CA69446, CA69467, CA69631, and CA69638), the Research Triangle Institute Informatics Support Center (RFP N02PC45022-46), the Specialized Program of Research Excellence (SPORE P50 CA83638 and CA113916), the Department of Defense Breast Cancer Research Program (05/0612), the Eileen Stein Jacoby Fund, the Breast Cancer Research Foundation, the Marianne and Robert MacDonald Foundation, the Komen Foundation, the Helsinki University Central Hospital Research Fund, the Academy of Finland (110663), the Finnish Cancer Society, the Sigrid Juselius Foundation, and the EU FP7 (223175, HEALTH-F2-2009-223175)"	FIS	Breast Cancer	
491	"This work was funded by the Spanish Ministries of Health, and Science ane Innovation (CB07/02/2005; FIS 08/1120, 08/1359, 08/1635, and 09/02483; RTICCC RD06/0020/1060 and RD06/0020/0028; Transversal Action Against Cancer; the Spanish Biomedical Research Centre Networks for Epidemiology and Public Health, and Rare Diseases; and the ""Ramon y Cajal"" Young Investigator Program), the Spanish National Society of Medical Oncology (2010), the Spanish Association Against Cancer (AECC 2010), the AGAUR Catalan Government Agency (2009SGR1489 and 2009SGR293; and the Beatriu Pinos Postdoctoral Program), the Ramon Areces Foundation (XV), the ""Roses Contra el Cancer"" Foundation, the Michael Cuccione Foundation for Childhood Cancer Research, Cancer Research-UK (C490/A10119, C1287/A8874, C1287/A10118, C5047/A8385, and C8197/A10123), the National Institute for Health Research (UK), the Association for International Cancer Research (AICR-07-0454), the Ligue National Contre le Cancer (France), the Association ""Le cancer du sein, parlons-en!"", the Dutch Cancer Society (NKI 1998-1854, 2004-3088, and 2007-3756), the Fondazione Italiana per la Ricerca sul Cancro (""Hereditary Tumors""), the Associazione Italiana per la Ricerca sul Cancro (4017), the Italian Ministero della Salute (RFPS-2006-3-340203 and ""Progetto Tumori Femminili""), the Italian Ministero dell'Universita' e Ricerca (RBLAO3-BETH), the Fondazione IRCCS Istituto Nazionale Tumori (INT ""5x1000""), the Fondazione Cassa di Risparmio di Pisa (Istituto Toscano Tumori), the National Breast Cancer Foundation (Australia), the Australian National Health and Medical Research Council (145684, 288704, and 454508), the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania, and South Australia, the Cancer Foundation of Western Australia, the German Cancer Aid (107054), the Center for Molecular Medicine Cologne (TV93), the National Cancer Institute (USA; CA128978 and CA122340), National Institutes of Health (RFA-CA-06-503, BCFR U01 CA69398, CA69417, CA69446, CA69467, CA69631, and CA69638), the Research Triangle Institute Informatics Support Center (RFP N02PC45022-46), the Specialized Program of Research Excellence (SPORE P50 CA83638 and CA113916), the Department of Defense Breast Cancer Research Program (05/0612), the Eileen Stein Jacoby Fund, the Breast Cancer Research Foundation, the Marianne and Robert MacDonald Foundation, the Komen Foundation, the Helsinki University Central Hospital Research Fund, the Academy of Finland (110663), the Finnish Cancer Society, the Sigrid Juselius Foundation, and the EU FP7 (223175, HEALTH-F2-2009-223175)"	FIS	Breast Cancer	
492	"This work was funded by the Spanish Ministries of Health, and Science ane Innovation (CB07/02/2005; FIS 08/1120, 08/1359, 08/1635, and 09/02483; RTICCC RD06/0020/1060 and RD06/0020/0028; Transversal Action Against Cancer; the Spanish Biomedical Research Centre Networks for Epidemiology and Public Health, and Rare Diseases; and the ""Ramon y Cajal"" Young Investigator Program), the Spanish National Society of Medical Oncology (2010), the Spanish Association Against Cancer (AECC 2010), the AGAUR Catalan Government Agency (2009SGR1489 and 2009SGR293; and the Beatriu Pinos Postdoctoral Program), the Ramon Areces Foundation (XV), the ""Roses Contra el Cancer"" Foundation, the Michael Cuccione Foundation for Childhood Cancer Research, Cancer Research-UK (C490/A10119, C1287/A8874, C1287/A10118, C5047/A8385, and C8197/A10123), the National Institute for Health Research (UK), the Association for International Cancer Research (AICR-07-0454), the Ligue National Contre le Cancer (France), the Association ""Le cancer du sein, parlons-en!"", the Dutch Cancer Society (NKI 1998-1854, 2004-3088, and 2007-3756), the Fondazione Italiana per la Ricerca sul Cancro (""Hereditary Tumors""), the Associazione Italiana per la Ricerca sul Cancro (4017), the Italian Ministero della Salute (RFPS-2006-3-340203 and ""Progetto Tumori Femminili""), the Italian Ministero dell'Universita' e Ricerca (RBLAO3-BETH), the Fondazione IRCCS Istituto Nazionale Tumori (INT ""5x1000""), the Fondazione Cassa di Risparmio di Pisa (Istituto Toscano Tumori), the National Breast Cancer Foundation (Australia), the Australian National Health and Medical Research Council (145684, 288704, and 454508), the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania, and South Australia, the Cancer Foundation of Western Australia, the German Cancer Aid (107054), the Center for Molecular Medicine Cologne (TV93), the National Cancer Institute (USA; CA128978 and CA122340), National Institutes of Health (RFA-CA-06-503, BCFR U01 CA69398, CA69417, CA69446, CA69467, CA69631, and CA69638), the Research Triangle Institute Informatics Support Center (RFP N02PC45022-46), the Specialized Program of Research Excellence (SPORE P50 CA83638 and CA113916), the Department of Defense Breast Cancer Research Program (05/0612), the Eileen Stein Jacoby Fund, the Breast Cancer Research Foundation, the Marianne and Robert MacDonald Foundation, the Komen Foundation, the Helsinki University Central Hospital Research Fund, the Academy of Finland (110663), the Finnish Cancer Society, the Sigrid Juselius Foundation, and the EU FP7 (223175, HEALTH-F2-2009-223175)"	FIS	Breast Cancer	
493	CD24 staining of mouse mammary gland cells defines luminal epithelial, myoepithelial/basal and non-epithelial cells.	CD24	myoepithelial	
494	Basal-like breast cancer and the BRCA1 phenotype.	BRCA1	breast cancer	
495	The basal phenotype of BRCA1-related breast cancer: past, present and future.	BRCA1	breast cancer	
496	Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers.	BRCA1	basal tumor	
497	 BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells.	BRCA1	breast cancers	
498	The pattern of expression of the microtubule-binding protein RHAMM/IHABP in mammary carcinoma suggests a role in the invasive behaviour of tumour cells.	RHAMM	carcinoma	
499	The pattern of expression of the microtubule-binding protein RHAMM/IHABP in mammary carcinoma suggests a role in the invasive behaviour of tumour cells.	RHAMM	tumour	
500	The pattern of expression of the microtubule-binding protein RHAMM/IHABP in mammary carcinoma suggests a role in the invasive behaviour of tumour cells.	IHABP	carcinoma	
501	The pattern of expression of the microtubule-binding protein RHAMM/IHABP in mammary carcinoma suggests a role in the invasive behaviour of tumour cells.	IHABP	tumour	
502	Receptor for hyaluronan-mediated motility correlates with centrosome abnormalities in multiple myeloma and maintains mitotic integrity.	Receptor for hyaluronan-mediated motility	centrosome abnormalities in multiple myeloma	
503	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population.	BRCA1	breast cancer	
504	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population.	BRCA1	breast cancer	
505	Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers.	LSP1	breast cancer	
506	Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers.	BRCA1	breast cancer	
507	Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers.	BRCA2	breast cancer	
508	Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.	BRCA1	breast cancer	
509	Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.	BRCA2	breast cancer	
510	Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.	BRCA1	breast cancer	
511	Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.	BRCA2	breast cancer	
512	 RAD51 135G C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies.	RAD51	breast cancer	
513	 RAD51 135G C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies.	BRCA2	breast cancer	
514	RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myeloma.	RHAMM	aggressive disease	
515	RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myeloma.	RHAMM	multiple myeloma	
516	Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas.	Vimentin	breast carcinomas	
517	Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas.	BRCA1	breast carcinomas	
518	Identification of a new APC/C recognition domain, the A box, which is required for the Cdh1-dependent destruction of the kinase Aurora-A during mitotic exit.	Cdh1	APC	
519	Identification of a new APC/C recognition domain, the A box, which is required for the Cdh1-dependent destruction of the kinase Aurora-A during mitotic exit.	Aurora-A	APC	
520	Aurora-A kinase regulates breast cancer-associated gene 1 inhibition of centrosome-dependent microtubule nucleation.	Aurora-A	breast cancer	
521	 Hyaluronan-mediated motility receptor gene single nucleotide polymorphisms and risk of breast cancer.	Hyaluronan-mediated motility receptor	breast cancer	
522	Inconsistent association between the STK15 F31I genetic polymorphism and breast cancer risk.	STK15	breast cancer	
